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SUMMARY 
Interleukin-1 (IL-1β) is a prototypic multifunctional cytokine. It not only mediates 
host inflammatory response in innate immunity, but also modulates antigen-specific 
immunity. It is implicated in the pathogenesis of autoimmune disease, such as 
rheumatoid arthritis. The margin between clinical benefits and toxicity of IL-1β in 
humans is exceedingly narrow. Therefore, its production and activity are tightly 
regulated events. IL-1β is mainly produced by monocytes and macrophages upon 
activation with microbial structures.  Dendritic cells (DCs) can be derived from 
monocytes. They are highly potent antigen presenting cells, which are central 
regulator of immune activation and tolerance. The regulation of IL-1β production in 
DCs is less clear. In this project, the underlying regulatory mechanisms of IL-
1β synthesis and secretion in DCs are investigated.  We observed that, in response to 
LPS, monocyte-derived DCs (moDCs) expressed IL-1β mRNA, synthesized pro-IL-
1β and processed IL-1β precursors but secret little mature IL-1β. FcγR stimulation of 
moDCs with immobilized IgG (imIgG) induced little IL-1β mRNA and protein 
synthesis. However, co-stimulation with LPS and imIgG resulted in dramatic increase 
in IL-1β secretion from moDCs. This was mediated through P2X7 receptor-dependent 
Ca2+ influx. It was ablated by the P2X7R antagonist oxidized ATP and the Ca2+ 
chelator EGTA. Blocking of FcγRII inhibited IL-1β secretion from moDCs. In 
addition, using specific signaling inhibitors, we identified PI3-K and P38 MAPK as 
negative modulators for IL-1β secretion, whereas inhibitors of JNK, ERK MAPK and 
 VII
RAC1 inhibited its secretion. Altogether, IL-1β production is rigidly controlled in 
DCs and this may be abrogated by prolonged exposure to tissue-deposited immune 
complexes found under autoimmune conditions.  
 VIII
LIST OF TABLES 
1.1 Comparison between innate immunity and adaptive immunity    2 
1.2 Comparison of different DC subsets          8 
1.3 Toll-like receptors and their ligands         21 
1.4 Phagocytic receptors for microbes          29 
1.5 General characteristics of human FcγRs        33 
2.1 Primers used in this study            58 
2.2 Reverse transcription reaction mixture (20 µl)       60 
2.3 Real time PCR reaction mixture (10 µl)        62 
2.4 Stimuli used in this study            63 
2.5 Antibodies used in this study           64 
2.6 Inhibitors used in this study           65 
2.7 Caspase-1 activity assay reaction mixture        70 
3.1 Effect of LPS and imIgG stimulation on IL-1β gene transcription   87 
 
 IX
LIST OF FIGURES 
1.1 DC development, differentiation and maturation       7 
 
1.2 Maturation of DCs             10 
 
1.3 In vitro monocyte-derived DC model         17 
 
1.4 Phylogenetic tree of human TLRs          20 
 
1.5 TIR domain-containing adaptors and TLR signaling      26 
 
1.6 Receptor and signaling interactions during phagocytosis of microbes  30 
 
1.7 Structural diversity and heterogeneity of human FcγRs     32 
 
1.8 Mechanisms of antibody-mediated inflammation      34 
 
1.9 Cellular activation by FcγRIII aggregation        38 
 
1.10 Signaling pathways triggered by BCR-FcγRII co-ligation    38 
 
1.11 Steps in the processing and secretion of IL-1β       50 
 
3.1 Phenotypic properties of monocytes and moDCs      75 
 
3.2 IL-1β and TNF-α secretion from LPS-stimulated moDCs and monocytes 77 
 
3.3 IL-1β secretion from moDCs and monocytes upon TLRs activation  78 
 
3.4 Effect of IL-4 and GM-CSF on IL-1β secretion from LPS-stimulated 
monocytes               79 
 
3.5 IL-1β secretion from LPS-stimulated moDCs and macrophages   80 
 
3.6 IL-1β synthesis and processing by LPS-stimulated moDCs    81 
 
3.7 IL-1β secretion from DH5α-stimulated moDCs       82 
 
3.8 IL-1β secretion from LPS/ imIgG-co-stimulated moDCs     84 
 
3.9 IL-1β secretion from LPS/ imIgG-co-stimulated monocytes     85 
 
3.10 IL-1β secretion from moDCs with imIgG and TLR ligand co-stimulation  86 
 X
 
3.11 IL-1β synthesis and processing by activated moDCs      89 
 
3.12 Caspase-1 activity in activated moDCs         90 
 
3.13 FcγR expression profiles on moDCs by flow cytometry     92 
 
3.14 Effect of specific FcγR blockade on IL-1β secretion from LPS/ 
imIgG-co-simulated moDCs            93 
 
3.15 Effect of signaling inhibitors on IL-1β secretion from LPS/ 
imIgG-co-stimulated moDCs           95 
 
3.16 Effect of signaling inhibitors on IL-1β secretion from LPS-stimulated 
moDCs                96 
 
3.17 Ionomycin triggers IL-1β secretion from LPS-stimulated moDCs   98 
 
3.18 EGTA inhibits IL-1β secretion from LPS/ imIgG-co-stimulated moDCs  99 
 
3.19 P2X7R gene expression in activated moDCs          101 
 
3.20 oATP inhibits ATP-promoted IL-1β secretion from LPS-stimulated moDCs  
   102 
3.21 oATP inhibits imIgG-promoted IL-1β secretion from LPS-stimulated moDCs  
   103 
3.22 Conditioned medium from imIgG-activated moDCs elicits IL-1β secretion 


















MANUSCRIPT IN PREPARATION 
 
1. Xiaowei Wu, Linda Wang, Boon King Teh and Jinhua Lu 
Toll-like receptor activation elicits IL-1β formation inside dendritic cells but its 
secretion requires Fcγ receptor II (FcγRII) stimulation 
 XII
ABBREVIATIONS 
Nucleotides containing adenine, cytidine, guanine and thymine are abbreviated as A, 
C, G, and T. Other abbreviations are defined where they first appear in the text. The 
frequently used abbreviations in this thesis are listed below. 
Ag    antigen 
ATP   adenosine triphosphate 
APC   antigen presenting cell 
bp    base pair 
BCS   bovine calf serum 
Ca2+   calcium 
cDNA   complementary deoxynucleotidic acid 
CIA   collagen-induced arthritis 
DAG   diacylglycerol 
DC    dendritic cell 
DMSO   dimethyl sulphoxide 
dNTP   deoxynucleoside triphosphate 
EGTA   ethylene glycol-bis (2-aminoethylether)-N,N,N’,N’-tetraacetic acid 
ELISA   enzyme-linked immunosorbent assay 
ER    endoplasmic reticulum 
ERK   extracellular signal-regulated kinase 
E. coli   Escherichia Coli 
 XIII
FcγR   Fc receptor for IgG 
FITC   fluorescein isothiocyanate 
GM-CSF  Granulocyte macrophage colony-stimulating factor 
h    hour(s) 
hIgG   human IgG 
IC    immune complex 
IFN    interferon 
Ig    immunoglobulin 
IL    interleukin 
IL-1β   interleukin 1 beta 
imDC   immature dendritic cell 
imIgG   immobilized IgG 
IP3    inositol 1,4,5-trisphosphate 
JNK   Jun amino-terminal kinase 
kDa    kilodalton(s) 
LDH   lactate dehydrogenase 
LPS   lipopolysacchride 
LPS/ imIgG  lipopolysacchride and immobilized IgG 
imIgG   immobilized IgG 
ITAM   immunoreceptor tyrosine-based activation motif 
ITIM   immunoreceptor tyrosine-based inhibitory motif 
 XIV
MAPK   mitogen-activated protein kinase 
M-CSF   macrophage colony-stimulating factor  
mDC   mature dendritic cell 
moDC   monocyte-derived dendritic cell 
MHC   major histocompatibility complex 
mIL-1β   mature IL-1β 
min    minute(s) 
MMP   matrix metalloprotease 
mRNA   messenger ribonucleic acid 
MyD88   myeloid differentiation factor 88 
NF-IL6-CREB NF-IL6-cAMP response element binding site 
NF-κB   nuclear transcription factor-κB 
NK cells  natural killer cells 
oATP   oxidized ATP 
OD    optical density 
PAMP   pathogen-associated molecular pattern 
PBMC   peripheral blood mononuclear cells 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PGN   peptidoglycan 
PKC   protein kinase C 
 XV
PH domain  pleckstrin homology domain 
PI3-K   phosphatidylinositol 3-kinase 
PIP2   phospholipid phosphatidylinositol (4,5)-bisphosphate 
PIP3   phosphatidylinositol (3,4,5)-trisphosphate 
PLCγ   phospholipase-Cγ 
pro-IL-1β  IL-1β precursor 
PRR   pattern recognition receptor 
P2X7R   P2X7 purinoceptor 
RA    rheumatoid arthritis 
RNA   ribonucleic acid 
R-PE   R-phycoerythrin 
RT-PCR   reverse transcriptase-polymerase chain reaction 
SDS   sodium dodecyl sulphate 
sec    second(s) 
SH2   Src homology 2 domain 
SHIP    Src homology 2-containing inositol polyphosphate 5'-phosphatase 
TLR   toll-like receptor 
TNF   tumor necrosis factor 
TRAF6   tumor necrosis factor receptor-associated factor 6 
Tris    tri-hydorxymethyl-aminomethane 
µl    microliter(s) 
 XVI
µg    microgram(s) 
 XVII
CHAPTER 1 INTRODUCTION 
1.1 Overview of the immune system 
The immune system is a remarkable defense system that has evolved to protect 
multicellular hosts from the invasion of pathogenic microorganisms and the growth of 
tumor cells. This is critically dependent on its ability to discriminate between foreign 
molecules and the body’s own cells and proteins. Once a foreign organism is 
recognized, the immune system enlists a variety of cells and molecules to mount an 
appropriate response so as to eliminate or neutralize the invading organism.  
 
In mammals, the immune system can be divided into two branches: innate immunity 
and adaptive immunity (Janeway, 1992). Innate immunity, also known as natural or 
native immunity, refers to the host’s basic resistance to disease that exists before 
infection. The innate immune system includes several immunoregulatory components, 
such as complement, natural killer (NK) cells, phagocytic cells and interferons (IFNs) 
(Fearon and Locksley, 1996). Cells of the innate immune system express a restricted 
number of germline-encoded receptors to recognize conserved products of microbial 
metabolism produced by microbial pathogens (Janeway and Medzhitov, 2002). On the 
other hand, adaptive immunity, also known as acquired immunity, develops as a 
response to infection and increases in magnitude and defensive capabilities with each 
successive exposure to a particular microbe (Abbas et al., 2000a). B and T 
lymphocytes constitute the adaptive immune system and detect antigens in a highly 
specific manner using a huge repertoire of antigen receptors generated by somatic 
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gene recombination (Fearon and Locksley, 1996). Table1.1 summarizes the distinct 
features of these two immune systems.  
 
Table 1.1 Comparison between innate immunity and adaptive immunity 
Property Innate Immunity Adaptive Immunity 
Receptors z Encoded in germline 
 
 
z Rearrangement is not 
necessary 
z Limited diversity 
z Encoded by genes produced by 
somatic recombination of gene 
segments 
z Rearrangement is necessary 
 
z Greater diversity 
Distribution of 
receptors 
z Nonclonal: all cells of a class 
identical 
z Clonal: all cells of a class 
distinct 
Recognition z Conserved molecular patterns 
(e.g. LPS, mannans, glycans) 
z Details of molecular structures 
(e.g. proteins, peptides, 
carbohydrates) 
Discrimination of 
self and nonself 
z Perfect: selected over 
evolutionary time 
z Imperfect: selected in individual 
somatic cells 
Action time z Immediate activation of 
effectors 
z Delayed activation of effectors 
Response z Co-stimulatory molecules 
z Cytokines (e.g. IL-1β, IL-6) 
z Chemokines (e.g. IL-8) 
z Clonal expansion or anergy 
z IL-2 
z Effector cytokines (e.g. IL-4, 
IFN-γ) 
Table with modifications from (Janeway, Jr. and Medzhitov, 2002) 
(LPS: lipopolysacchride) 
 
Two important links exist between the innate and adaptive immune system. First, the 
innate immune system can instruct the adaptive immune system about the nature of 
the pathogenic challenge. T and B cells of the adaptive immune system cannot discern 
the nature of antigens (Janeway, 1992), though they possess great variability in 
antigen recognition. This accounts for the adverse response of autoimmune disease, 
allergy and allograft rejection. Therefore, upon pathogen infection, antigen presenting 
 2
cells (APCs) of the innate immune system provide the alerting signal through the 
surface expression of co-stimulatory molecules, such as CD80 and CD86 (Fearon and 
Locksley, 1996; Janeway and Medzhitov, 2002). The most important APCs are the 
dendritic cells (DCs), which guard against infection in virtually all tissues 
(Banchereau and Steinman, 1998). Second, adaptive immune system uses and 
enhances many of the effector mechanisms of innate immunity to eliminate microbes 
(Abbass et al., 2000a). For example, antibodies produced by B cells opsonize 
microbes and form immune complexes (ICs). These ICs are more effectively captured 
by phagocytes via Fc receptors for antigen presentation (Guermonprez et al., 2002). 
Thus, the interplay of these two arms of the immune system gives optimal host 
defense.  
 
1.2 Mononuclear phagocytes 
The mononuclear phagocytes comprise a family of cells that share common 
haematopoietic precursors and are distributed via the blood stream, as monocytes, to 
all tissues (Gordon, 1995). Within these tissues, the cells undergo maturation and 
differentiation into various cell types (macrophages, myeloid-derived DCs and 
osteoblasts), which perform specific housekeeping and immunological functions. 
Mononuclear phagocytes are important effector cells, which phagocytose microbes 
and produce cytokines to recruit and activate other immune cells. They also function 
as APCs, i.e. they present antigen to T lymphocytes and produce membrane and 




During ontogeny, the yolk sac produces haematopoietic stem cells which migrate to 
the foetal liver and develop into immature mononuclear phagocytes (Naito and Wisse, 
1977; Deimann and Fahimi, 1978; Deiman and Fahimi, 1997). Soon after 
haematopoiesis begins in the foetal liver, monocytes appear in the circulation (Metcalf 
and moore, 1971; Keleman et al., 1979; (Cline and Moore, 1972). In adults, the bone 
marrow is the only source of monocytes. There is considerable evidence to suggest 
that monocytes and neutrophils share common progenitor cells, the colony-forming 
unit-granulocyte-macrophages (CFU-GMs), in the bone marrow (Metcalf, 1971). For 
monocytic differentiation, CFU-GM subsequently gives rise to monobalsts. Each 
monoblast divides into two promonocytes, each of which further divide to form two 
daughter monocytes (van Furth and Diesselhoff-Den Dulk, 1970). Monotyes are 
released into the blood circulation, and upon emigration from the microvasculature 
into tissues, undergo maturation into macrophages.  
 
A series of growth factors and cytokines collectively influence monocytopoiesis. 
Interleukin 3 (IL-3), granulocyte macrophage colony-stimulating factor (GM-CSF) 
and macrophage colony-stimulating factor (M-CSF) (Jones and Millar, 1989) 
stimulate the mitotic activity of monocyte precursors, whereas IFN α/β (Perussia et 
al., 1983), prostaglandin E (PGE) (Kurland et al., 1978; Pelus et al., 1979), and factor 
increasing monocytopoiesis (FIM) have the opposite effect (Metcalf, 1990).  
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 Under normal steady-state conditions, monocyte production amounts to 
approximately 0.62×105 cells per hour (Van Furth et al., 1973). However, during 
inflammation, faster division and shorter cell cycle time result in an elevation of 
monocyte production and hence a large number of circulating monocytes. Monocytes 
enter the circulation within 24 h of their formation (van Furth and Sluiter, 1986). After 
that, they circulate for about 25 h before extravasation. Their transit circulation time is 
shortened during an inflammation as they actively migrate to inflammatory site.  
 
1.2.2 Dendritic cells 
DCs were first described in 1868 by Paul Langerhans as the stellate-shaped epidermal 
cells, but mistaken for cutaneous nerve cells (Langerhans, 1868). Almost a century 
later, Steinman and Cohn discovered these cells in mouse spleen and applied the term 
“dendritic cells” based on their unique morphology (Steinman and Cohn, 1973). Now 
it is widely accepted that DCs represent discrete leukocyte populations, which are 
highly specialized APCs, with the unique ability to induce primary immune responses 
(Hart, 1997; Steinman, 1991). 
 
Four stages of DC development have been delineated, including: (i) bone marrow 
progenitors, (ii) circulating precursor DCs, (iii) tissue-residing immature DCs 
(imDCs), and (iv) mature DCs (mDCs) in secondary lymphoid organs. DC 
progenitors in the bone marrow give rise to precursors that patrol through blood and 
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lymphatics. DC precursors home to tissues, where they reside as immature cells with 
high phagocytic capacity. In response to infection or tissue damage, imDCs capture 
antigen (Ag) and subsequently migrate to the lymphoid organs. There they become 
mDCs and select rare Ag-specific T cells, thereby initiating immune responses. 
 
1.2.2.1 Heterogeneity of dendritic cell subsets 
imDCs are continuously produced from hematopoietic stem cells within the bone 
marrow. FLT-3 ligands, and to a lesser extent GM-CSF, may represent the key DC 
growth and differentiation factors in vivo (Pulendran et al., 2001). CD34+ 
hematopoietic stem cells differentiate into common lymphoid progenitors (CLP) and 
common myeloid progenitors (CMP) in the bone marrow (Fig. 1.1). CD34+ CMPs 
appear to differentiate into CD34+CLA+ and CD34+CLA- populations, which 
subsequently differentiate into CD11c+CD1a+ and CD11c+CD1a- DCs, respectively 
(Strunk et al., 1997). CLA stands for cutaneous lymphocyte-associated antigen. While 
CD11c+CD1a+ DCs migrate into the skin epidermis and become Langerhans cells, 
CD11c+CD1a- DCs migrate into the skin dermis and other tissues, and become 
interstitial DCs (Ito et al., 1999). The CD34+ stem cell-derived Langerhans cells and 
interstitial DCs display different phenotypes and functions (Caux et al., 1997) (Table 
1.2A). CMP and CLP also give rise to two types of DC precursors (pre-DC) 
respectively in the bone marrow, namely monocytes (myeloid pre-DC1s) and 
plasmacytoid cells (lymphoid pre-DC2s) (Liu, 2001). Pre-DC1s and pre-DC2s display 
many different properties (Table 1.2B) (Liu, 2001). Moreover, distinct features have 
 6






Figure 1.1 DC development, differentiation and maturation CD34+ hematopoietic 
stem cells differentiate into CMPs and CLPs. The CMPs differentiated into 
CD34+CLA+ and CD34+CLA- progenitor cells, which differentiate in CD11c+CD1a+ 
skin epidermis Langerhans cell and skin dermis and other tissures CD11c+CD1a- 
interstitial DCs respectively. CMP and CLP also give rise to monocytes (pre-DC1) 
and plasmacytoid cells (pre-DC2) in bone marrow. Monocytes migrate to the blood 
and then to extravascular tissues to diffentiate into myeloid DCs (DC1). Plasmacytoid 






Table 1.2 Comparison of different DC subsets 
A. Difference between Langerhans cells and interstitial DCs 
 Langerhans cells Interstitial DCs 
Phenotype   
CD1a + - 
CD2 - + 
CD9 - + 
CD68 - + 
Factor XIIIa - + 
E-cadherin + - 
Birbeck Granule/Lag- antigen + - 
Function   
Macrophinocytosis - + 
IL-10-production - + 
B cell activation +/- + 
CD8 T cell-priming +++ + 
 
B. Difference between pre-DC1 and pre-DC2 
 Pre-DC1 Pre-DC2 
Phenotype   
Myeloid marker + - 
CD11b + - 
CD11c + - 
CD13 + - 
CD14 + - 
CD33   
Lymphoid marker   
Pre-Tα - + 
Ig γ-like 14.1 - + 
Spi-B - + 
Pattern recognition receptors   
Mannose R +/- - 
CD1a, b, c, d +/- - 
Other differentially expressed antigens   
CD4 + ++ 
CD45RA - + 
CD45RO + - 
IL-3R + +++ 
GM-CSFR ++ + 
Function   
Phagocytosis & kill bacteria ++ - 
IFN-α/β production + ++++ 
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C. Difference between CD11c+DCs and pre-DCs 
 CD11c+DCs pre-DCs 
Phenotype   
Dendrites or veils + - 
Co-stimulatory molecules moderate low 
Mobility high low 
Colonization non-lymphoid tissues 
without stimulation 
yes no 
Function   
T cell activation moderate no 
Innate immunity  low high 
Tables with modifications from (Liu, 2001) 
 
1.2.2.2 DC maturation and migration 
DC maturation is a pivotal event in the control of innate and adaptive immunity. It is a 
continuous process initiated in the periphery upon antigen encounter and /or 
inflammatory cytokines and completed during the DC-T cell interaction. This process 
is associated with distinct phenotypic and functional changes (Banchereau et al., 2000) 
(Fig. 1.2). mDCs down-regulate cell surface expression of endocytic/phagocytic 
receptors while up-regulating the expression of molecules that are involved in 
interaction with T cells, e.g. Major Histocompatibility Complex (MHC) molecules, 
CD40, CD54, CD80, CD86. In human DCs, CD83 is specified as a DC maturation 
marker although its function is not clear (Zhou and Tedder, 1996). Major changes in 
morphology are also observed, including a loss of adhesive structures, cytoskeleton 
reorganization, and acquisition of high cellular motility (Winzler et al., 1997). In 
addition, DC maturation is intimately linked with their migration from peripheral 
tissue to the draining lymphoid tissues. In order to do so, mDCs reduce the expression 
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of chemokine receptors CCR1, CCR5 and CCR6 which recognize inflammatory 
chemokines and up-regulate CCR7 which recognizes lymphocyte chemokines (Dieu 
et al., 1998; Sozzani et al., 1998). Altogether, these changes culminate in the complete 




Figure 1.2 Maturation of DCs The left side of the scheme shows the factors 
inducing progression from one stage to another; the right side shows the main 
properties of each differentiation/maturation stage. (dsRNA: double-stranded RNA; 





Numerous factors induce dendritic cell maturation, including: (i) pathogen-related 
molecules such as LPS, LTA, PGN, dsRNA and flagellin; (ii) pro-inflammatory 
mediators, i.e. TNF-α, IL-1β and PGE; (iii) ICs; (iv) T cell-derived signals, i.e. 
CD40L, IFN-γ and TNF-α; and (iv) tissue damage-derived signals, such as heat shock 
proteins (Banchereau et al., 2000; Rossi and Young, 2005). These different activation 
signals may act synergistically and regulate each other.  
 
1.2.2.3 Antigen uptake, processing and presentation by DCs 
DCs are professional APCs, which take up antigens in peripheral tissues, process them 
into proteolytic peptides, load these peptides onto MHC molecules and present the 
MHC-peptide complex to T cells.  
 
Immature tissue-resident DCs are very efficient in Ag capture. They internalize Ag by 
utilizing multiple pathways. DCs capture antigen molecules through 
receptor-mediated endocytosis. This pathway allows the uptake of macromolecules 
through specialized regions of the plasma membrane, termed coated pits. The 
receptors involved include C-type lectin receptors, e.g. mannose receptor and 
DEC-205 (Engering et al., 1997; Jiang et al., 1995); Fcγ receptor typeI and II (Fanger 
et al., 1996); complement receptor 3 and 4 (Reis e Sousa et al., 1993), and scavenger 
receptors (Platt et al., 1998). Particulate antigens are internalized by phagocytosis, 
which is generally mediated by the same receptors as for endocytosis. This process is 
actin dependent and requires membrane ruffling and the subsequent formation of large 
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intracellular vacuoles. imDCs were reported to phagocytose almost any bacteria (Bell 
et al., 1999) and internalize apoptotic and necrotic bodies as well (Albert et al., 1998). 
Soluble antigens are captured by maropinocytosis, which involves actin-driven 
engulfment of large amount of fluid and solutes. In imDCs, macropinocytosis is 
constitutive (Sallusto et al., 1995), allowing DCs to rapidly and nonspecifically 
sample microenvironment.  
 
After Ag uptake, DCs process them into proteolytic peptides and load these peptide 
onto MHC class I (MHCI) and II (MHCII) molecules. The peptide loading is achieved 
in multiple ways. (i) The MHCI-restricted pathway. Most peptides that are loaded on 
MHCI are generated by proteasome degradation of newly synthesized ubiquitinate 
proteins (Guermonprez et al., 2002). The resulting peptides are transferred to 
endoplasmic reticulum (ER) by specialized peptide transporters and loaded on MHCI. 
Once loaded with peptides, MHCI is rapidly transferred through the Golgi apparatus 
to the plasma membrane. DCs present self- or virus-derived endogenous antigens 
through MHCI. However, exogenous peptides, originating from phagocytosed 
particulated antigens or ICs, may also be presented by MHCI (Norbury et al., 1997; 
Shen et al., 1997). This property is termed cross-presentation. (ii) The 
MHCII-restricted pathway. Exogenous Ags are efficiently captured by DCs, degraded 
in endosomes and directed towards MHCII-rich compartments (MIIC) (Kleijmeer et 
al., 1995; Nijman et al., 1995). MIIC contains HLA-DM. HLA-DM promotes the 
catalytic removal of MHCII-associated invariant chain peptide and enhances peptide 
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binding to MHCII (Castellino et al., 1997; Cresswell, 1996). Once loaded with 
peptides, MHCII/peptide complexes are exposed on the plasma membrane. (iii) The 
CD1-restricted pathway. CD1 presents microbial lipids and glycolipids-containing Ag 
to a large repertoire of T cells (Matsuda and Kronenberg, 2001).  
 
1.2.2.4 Immune regulation by DCs 
DCs are the single most central player, providing an essential link between innate and 
adaptive immunity (Palucka and Banchereau, 1999a). DCs are exceptionally potent 
immune response initiator under inflammatory conditions (Banchereau and Steinman, 
1998; Fearon and Locksley, 1996), yet are also critical to the induction and 
maintenance of self-tolerance in the steady state (Bonifaz et al., 2002; Hawiger et al., 
2001; Liu et al., 2002). The major immune regulatory function of DCs can be 
summarized as follows: 
 
(i) T cell activation and differentiation 
The ability to prime naïve T cells constitutes a unique and critical function of DCs. 
Recognition of peptide-MHC complexes on DCs by Ag-specific T cell receptor (TCR) 
constitutes “signal one” in DC-T cell interaction (Banchereau and Steinman, 1998). 
CD4+ T cells are restricted to recognize MHCII-associated peptides, while CD8+ cells 
are MHCI-restricted. Co-stimulatory molecules, expressed on DCs, i.e. CD80, CD86, 
CD40, interact with ligands or counter-receptors on T cells, constituting “signal two”. 
This signal is required to sustain T cell activation (Caux et al., 1994; Inaba et al., 
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1995). The responses of T cells are influenced by features of the antigen, the APCs 
and the environment in which T cells encounter antigens. Effective priming of naïve T 
cells results in their clonal expansion and differentiation into cytokine-secreting 
effector cells and memory cells (Mempel et al., 2004).  
 
(ii) T cell tolerance 
There is increasing evidence that DCs in situ induce antigen specific 
unresponsiveness or tolerance in central lymphoid organs and in the periphery. In the 
thymic medulla, DCs present self-antigens in the context of MHC molecules and 
assist in deletion of self-reactive T cells (Hogquist et al., 2005). Moreover, under 
steady-state conditions, a small fraction of resident DCs capture self-antigens or 
apoptotic bodies that are derived from normal cell turn over in peripheral tissues 
(Huang et al., 2000). And they mature “spontaneously”, migrate to the draining lymph 
nodes and present antigens to T cells. Tolerance occurs through Ag-reactive T cell 
deletion (Heath and Carbone, 2001) or the induction of regulatory T cells (Tr) (Fujii et 
al., 2003). Tr cells can suppress immune responses via cell-cell interactions and /or 
production of IL-10 and TGF-β (Levings et al., 2002).  
 
(iii) B cell development 
DCs are now known to have major effects on B-cell growth and immunoglobulin 
secretion (Banchereau and Steinman, 1998). DCs activate and expand T-helper cells, 
which in turn induce B-cell growth and antibody production (Bell et al., 1999). 
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Besides, by secretion of soluble factors, DCs stimulate the production of antibodies 
directly and the proliferation of B cells that have been stimulated by CD40L on 
activated T cells (Dubois et al., 1997). DCs also orchestrate immunoglobulin 
class-switching of T cell activated B cells. While IL-10 and TGF-β can induce 
secretion of IgA1, expression of IgA2 appears to be strictly dependent on a direct 
interaction between B cells and DCs (Fayette et al., 1997).  
 
(iv) NK and NKT cell activation 
Recent data have established an important role for DCs in innate immune responses 
by NK and NK T cells (Rossi and Young, 2005). Precursors of CD11c-DCs may 
activate NK cells through the release of IFN-α, thereby leading to enhanced antiviral 
and antitumor activity of NK cells (Cella et al., 1997; Palucka and Banchereau, 1999b; 
Siegal et al., 1999). DCs at later stages of differentiation may regulate the activity of 
NK/NK T cells through the release of IL-12, IL-15 and IL-18 (Geldhof et al., 1998; 
Shah, 1987). DCs presenting the synthetic glycolipid α-galactosyl ceramide on CD1d 
can activate NK T cells to produce IFN-γ and promote resistance to tumors (Fujii et 
al., 2002).  
 
1.2.2.5 In vitro human DC differentiation models 
In vitro studies of the differentiation of human DCs have been influenced greatly by 
the aim of optimizing culture systems to allow an efficient production of DCs for use 
in cancer immunotherapy. Two main protocols have been defined to generate DCs 
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from either monocytes (Sallusto and Lanzavecchia, 1994) or CD34+ precursors (Caux 
et al., 1996). In this project, we use mococyte-derived DCs. 
 
Peripheral blood mononuclear cells (PBMC) can be isolated from blood or buffy coat 
preparations by density centrifugation on Ficoll-Hypaque. Monocytes are separated 
from lymphocytes using several methods. The most common procedure for monocyte 
isolation is based on adhesion to plastic surface (Bennett and Breit, 1994). The 
advantage of this method is that it is inexpensive and relatively easy to perform. The 
purity of cells isolated by this method can vary. Alternative methods are 
immuneselection, such as magnetic cell sorting, and centrifugal elutriation. Immune 
selection is too expensive for frequent isolation, whereas centrifugal elutriation 
requires expensive equipment and extensive experience. A simple and inexpensive 
method for monocyte isolation does not exist (Bennett and Breit, 1994). 
 
imDCs can be generated from monocytes with GM-CSF and IL-4 (Sallusto and 
Lanzavecchia, 1994) (Fig 1.3). These cells have typical dendritic morphology, 
express high levels of MHCI and II, CD1, FcγRII, CD40, B7, CD44, and ICAM-1, 
and lack CD14. Cultured DCs are highly stimulatory in mixed leukocyte reaction 
(MLR) and are also capable of triggering cord blood naive T cells. Incubation with 
maturation mediators such as TNF-α, LPS, IFN-γ or CD40L, drives imDCs into a 
mature state although slight phenotypical or functional differences have been reported 
(Timmerman and Levy, 1999). 
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Figure 1.3 In vitro monocyte-derived DC model In vitro, DCs can be generated 
with GM-CSF and IL-4 and matured by TNF-a or other mediators (Ardavin et al., 
2001).  
 
1.3 Pattern recognition receptors  
The basis of innate immune system activation is pattern recognition (Janeway and 
Medzhitov, 2002). Many metabolic pathways and individual gene products are unique 
to microorganisms and essential for their survival. Therefore, these conserved 
products are viewed as molecular signatures of microbial invaders, and named 
pathogen-associated molecular patterns (PAMPs). Accordingly, the receptors of innate 
immune system that recognize PAMPs are called pattern recognition receptors (PRRs) 
(Janeway, 1989). The innate immune system uses various PRRs that are expressed on 
the cell surface, in intracellular compartments, or secreted into the blood stream and 
tissue fluids (Medzhitov and Janeway, 1997). The cell surface PRRs includes two 
major classes (Aderem and Underhill, 1999; Janeway and Medzhitov, 1998): (i) those 
that capture pathogens and mediate phagocytosis and endocytosis, such as mannose 
receptor (MR), scavenger receptor (SR) and complement receptor (CR); and (ii) those 
that sense pathogens and lead to the activation of pro-inflammatory pathways, e.g. 
Toll-like receptors (TLRs). The principle functions of PRRs include: opsonization, 
activation of complement and coagulation cascades, phagocytosis, activation of 
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pro-inflammatory signaling pathways and induction of apoptosis (Janeway, 1989; 
Janeway and Medzhitov, 1998; Medzhitov and Janeway, 1997). Besides the above 
two major types of cell-surface PRRs, there are also several secreted PRRs, e.g. 
surfactant proteins A (SP-A) & D (SP-D), the mannose lectin (MBL) (Lu et al., 2002), 
C-reactive protein (CRP), serum amyloid protein (SAP) (Schwalbe et al., 1992), 
LPS-binding protein and CD14. Several other PRRs are expressed in the cytosol 
where they detect intracellular pathogens and induce responses that block pathogen 
replication, such as protein kinase PKR (Clemens and Elia, 1997), nucleotide-binding 
oligomerization domain (NOD) proteins (Hammond-Kosack and Jones, 1997) and 
2’-5’-oligoadenylate synthase (OSA) (Kumar and Carmichael, 1998). Among the cells 
that bear PRRs are macrophages, DCs, mast cells, neutrophils, eosinophils, and NK 
cells (Janeway and Medzhitov, 2002). In this project, we focus on TLRs. 
 
1.3.1 TLRs 
TLRs are a family of type I transmembrane glycoproteins. It contains an 
amino-terminal leucine-rich repeat (LRR) and carboxyl-terminal Toll/interleukin-1 
receptor (TIR) homology domain (Rock et al., 1998). LRRs are found in a diverse set 
of proteins in which they are involved in ligand recognition and signal transduction 
(Kobe and Deisenhofer, 1995). The number of LRRs varies in different TLRs. The 
TIR domain is a conserved protein-protein interaction module, which is found in the 
Drosophila Toll family of receptors, the IL-1 receptor (IL-1R) family in mammals and 
several cytoplasmic proteins. These cytoplasmic proteins function as adaptor proteins 
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in TLR signal transduction. The TIR domain in these proteins interact with the TIR 
domains of the receptors, while other domains in these proteins recruit the 
downstream signaling components (Bin et al., 2003; Horng et al., 2001; Medzhitov et 
al., 1998; Yamamoto et al., 2003a).  
 
The Drosophila Toll is the prototype of TLRs, which was originally identified for its 
role in the development of dorso-vental polarity of the fruitfly embryo (Hashimoto et 
al., 1988; Lemaitre et al., 1996). It was later found to be involved in anti-fungal 
immunity (Lemaitre et al., 1996). Sequencing of the Drosophila genome reveals that it 
contains nine genes that encode Toll and related receptors (Tauszig et al., 2000). Ten 
TLR genes have been identified in mice and humans (Akira et al., 2001).  
 
A comparison of the amino acid sequences of human TLRs shows that these receptors 
can be divided into five groups (Gangloff et al., 2003; Takeda et al., 2003): the TLR3, 
TLR4, TLR5, TLR2 and TLR9 subfamilies. The TLR2 subfamily is composed of 
TLR1, TLR2, TLR6 and TLR10, whereas the TLR9 subfamily consists of TLR7, 









Fig 1.4 Phylogenetic tree of human TLRs The phylogenetic tree was derived form 
an alignment of the amino acid sequences for human TLRs using the neighbor-joining 
method (Takeda et al., 2003).  
 
1.3.1.1 TLR ligands 
Most ligands recognized by TLRs can be classified as PAMPs, which are exogenous 
ligands. However, endogenous non-PAMP ligands are also present, such as heat shock 
proteins and extracellular matrix degradation products (Takeda et al., 2003). The 
ligand specificity for TLRs was mostly identified in vitro using ligand binding assays 
or in vivo through generation of TLR knockout mice. Ligands for individual TLRs are 











Table 1.3 Toll-like receptors and their ligands 
TLR family Ligands (origin) References 
Tri-acyl lipopeptides (bacteria, mycobacteria) (Takeuchi et al., 2002) TLR1 
  Soluble factors (Neisseria meningitides) (Wyllie et al., 2000) 
Lipoprotein/lipopeptides (a variety of 
pathogens) 
(Aliprantis et al., 1999; 
Brightbill et al., 1999; 
Hirschfeld et al., 1999) 
Peptidoglycan (Gram-positive bacteria) 
Lipoteichoic acid (Gram-positive bacteria) 
(Schwandner et al., 1999; 
Underhill et al., 1999b; 
Yoshimura et al., 1999) 
Lipoarabinomannan (mycobacteria) (Means et al., 1999; 
Underhill et al., 1999b) 
A phenol-soluble modulin (Staphylococcus 
epidermidis) 
(Hajjar et al., 2001) 
Glycoinositolphospholipids (Trypanosoma 
Cruzi) 
(Campos et al., 2001) 
Glycolipids (Treponema maltophilum) (Opitz et al., 2001) 
Porins (Neisseria) (Massari et al., 2002) 
Zymosan (fungi) (Underhill et al., 1999a) 
Atypical LPS (Leptospira interrogans) 
Atypical LPS (Porphyromonas gingivalis) 
(Hirschfeld et al., 2001) 
TLR2 
  
HSP70 (host) (Asea et al., 2002; Vabulas et 
al., 2002) 
TLR3 Double-stranded RNA (virus) (Alexopoulou et al., 2001; 
Hemmi et al., 2000) 
LPS (Gram-negative bacteria) (Hoshino et al., 1999) 
Taxol (plant) (Byrd-Leifer et al., 2001) 
TLR4 
  
  Fusion protein (RSV) (Kurt-Jones et al., 2000) 
Envelope proteins (MMTV) (Rassa et al., 2002) 
HSP60 (Chlamydia pneumoniae) (Sasu et al., 2001) 
HSP60 (host) (Ohashi et al., 2000) 
HSP70 (host) (Dybdahl et al., 2002) 
Type III repeat extra domain A of fibronectin 
(host) 
(Okamura et al., 2001) 
Oligosaccharides of hyaluronic acid (host) (Termeer et al., 2002) 
Polysaccharide fragments of heparan sulfate 
(host) 









Fibrinogen (host) (Smiley et al., 2001) 
TLR5 Flagellin (bacteria) (Hayashi et al., 2001) 
TLR6 Di-acyl lipopeptides (mycoplasma) (Takeuchi et al., 2001) 
Imidazoquinoline (synthetic compounds) (Hemmi et al., 2002) 
Loxoribine (synthetic compounds) 
TLR7 
  
  Bropirimine (synthetic compounds) 
(Takeda et al., 2003) 
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TLR8 ?  
TLR9 CpG DNA (bacteria) (Hemmi et al., 2000) 
TLR10 ?  
Tables modified from (Takeda et al., 2003) 
 
1.3.1.2 Expression of TLRs by mononuclear phagocytes 
Monocytes and macrophages express mRNA for most TLRs except that relatively low 
levels of TLR3 mRNA were detected in these cells (Heinz et al., 2003; Muzio et al., 
2000). Expression of TLRs in DCs differs depending on the subsets. Northern blot 
analysis showed that myeloid DCs express mRNA for TLR1, 2, 3, 4, 5 and 8, while 
plasmacytoid DCs express TLR7 and TLR9 mRNA (Jarrossay et al., 2001; Krug et al., 
2001). In some other studies, TLR7 is also detected in myeloid DCs (Ito et al., 2002). 
TLR expression is also regulated during DC maturation. The expression of TLR1, 2, 4, 
5 decreased as DCs mature. But TLR3 expression increases upon DC activation 
(Muzio et al., 2000; Visintin et al., 2001). 
 
1.3.1.3 Signal transduction via TLRs 
Signaling pathways activated by TLRs can be divided into “shared” and “specific” 
pathways (Medzhitov, 2001). Except for TLR3, a shared pathway is activated by all 
TLRs as well as by IL-1R family of receptors, involving MyD88 as an adaptor protein. 
Specific pathways have been identified for TLR3 and TLR4, which are 




1.3.1.3.1 The MyD88-dependent signaling pathway 
Most members of the TLR and IL-1R family transduce signals utilizing MyD88 as 
adaptor molecule. MyD88-/- mice do not produce IL-1β, TNF-α, IL-6 and IL-12 in 
response to immunostimulatory components such as LPS (Kawai et al., 1999), PGN 
(Takeuchi et al., 2000b), lipoproteins (Takeuchi et al., 2000a), CpG DNA (Hacker et 
al., 2000), flagellin (Hayashi et al., 2001), or imidazoquinolines (Hemmi et al., 2002). 
The generally accepted MyD88-dependent pathway has been illustrated by Takeda 
and Akira as follows (Takeda and Akira, 2004) (Fig. 1.5). MyD88 has a TIR domain 
in its carboxy-terminus and a death domain in its aminol-terminus. Activation of 
TLRs or IL-1R recruits MyD88 to the receptor. The TIR domain of MyD88 binds to 
the TIR domains of activated TLRs, whereas the death domain interacts with the 
death domain of IL-1R associated kinase (IRAK) 1 and IRAK 4 (Burns et al., 1998; 
Medzhitov et al., 1998; Muzio et al., 1997; Wesche et al., 1997). Thus, the respective 
kinase domains on IRAKs are brought in close association. IRAK1, which is activated 
by phosphorylation by autophosphorylated IRAK4, interacts with tumor necrosis 
factor  
receptor-associated factor 6 (TRAF6) (Cao et al., 1996). The association of the 
IRAK/TRAF6 complex causes conformational change, leading to their disengagement 
from the receptor complex. The IRAK/TRAF6 complex then interacts at the 
membrane with another preformed complex consisting of TGF-β-activated kinase 
(TAK1) and its two adaptor proteins, TAK1-binding protein (TAB1) 1 and TAB2. 
This interaction induces phosphorylation of TAB2 and TAK1, resulting in the 
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translocation of both complexes into the cytosol. TAK1 is then activated in the 
cytoplasm by the ubiquitination system (Wang et al., 2001), leading to the activation 
of IκB kinase (IKK) complex. Activation of IKK leads to the phosphorylation and 
degradation of IκB, resulting in the release and translocation of NF-κB into the 
nucleus. The activation of TAK1 also leads to activation of p38, JNK and p42/p44 
mitogen-activated protein kinases (MAPKs). In short, the MyD88-dependent pathway 
signals via MyD88, IRAK, and TRAF6 and leads to NF-κB and MAPK activation.  
 
Recently, a second TIR domain-containing molecule-TIRAP/Mal, has been shown to 
be essential for the MyD88-dependent signaling pathway via TLR2 and TLR4 
exclusively. In TIRAP/Mal-/- mice, there was delayed NF-κB activation and no 
induction of TNF-α, IL-6 or IL-12p40 (Yamamoto et al., 2002). Responses to TLR2 
ligands were also completely abolished in these mice (Horng et al., 2002).  
 
1.3.1.3.2 The MyD88-independent signaling pathway 
A detailed analysis of MyD88-/- mice showed several unexpected features of the 
signaling downstream of TLR3 and TLR4 (Alexopoulou et al., 2001; Kaisho et al., 
2001; Kawai et al., 1999; Schnare et al., 2000; Takeuchi et al., 2000a). LPS and Poly 
(I:C), but not CpG or MALP-2, could induce the activation of NF-κB and MAPK. 
Activation of these signaling pathways through TLR3 and TLR4 occurred with 
delayed kinetics. And most importantly, it was insufficient to induce cytokine gene 
expression. These findings indicated the presence of MyD88-independent signaling 
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pathways for TLR3 and TLR4.  
Through MyD88-independent pathway, TLR3 and TLR4 mediate the activation of 
interferon regulatory factor 3 (IRF3) to induce IFN-β. IFN-β, in turn, activates signal 
transducer and activator of transcription 1 (STAT 1), leading to the induction of 
several IFN-induced genes that are protective against viral infections (Doyle et al., 
2002; Hoshino et al., 2002; Toshchakov et al., 2002). However, the molecular 
mechanism of upstream signaling is not clear. Two adaptor proteins, TRIF and TRAM, 
have been demonstrated to play a role. TLR3 and TLR4-mediated 
MyD88-independent IRF3 activation was severely impaired in TRIF-/- mice (Hoebe et 
al., 2003; Yamamoto et al., 2003a). TRAM-/- mice showed defects in cytokine 
production when challenged with TLR4 ligand, but not other TLR ligands. TLR4- but 
not TLR3-mediated MyD88-independent IFN-β production was abolished in these 
mice (Fitzgerald et al., 2003; Yamamoto et al., 2003b). Therefore, TRIF functions 





Figure 1.5 TIR domain-containing adaptors and TLR signaling MyD88 is an 
essential TIR domain-containing adaptor for the induction of inflammatory cytokines 
via all TLRs. TIRAP/Mal is a second TIR domain-containing adaptor that specifically 
mediates the MyD88-dependent pathway via TLR2 and TLR4. In the TLR4- and 
TLR3-mediated signaling pathways, a MyD88-independent pathway exists that leads 
to activation of IRF-3 via TBK1 and IKKε/IKKi. The TIR domain-containing adaptor 
TRIF mediates this MyD88-independent pathway (Takeda and Akira, 2004).  
 
1.3.1.4 Modulation of immune response by TLRs 
Recognition of microbial components by TLRs triggers activation of innate immunity, 
which in turn regulates adaptive immunity. In the regulation of innate immunity, 
TLRs appear to be directly involved in induction of antimicrobial activity. Microbial 
lipoproteins induce iNOS gene transcription via TLR2, indicated by the induced iNOS 
promoter activity in RAW 264.7 cells (Brightbill et al., 1999). TLR2 activation leads 
to nitric oxide-dependant and -independent killing of intracellular Mycobacterium 
tuberculosis in mouse and human macrophages respectively (Thoma-Uszynski et al., 
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2001). In addition, TLRs are likely to mediate the secretion of antimicrobial peptides 
in response to microbial stimuli at epithelial surface. LPS induces expression of 
mouse β-defensin-2, -3, and -6 (Lehrer and Ganz, 2002). Stimulation of the human 
lung epithelial cell line A549 with lipoprotein led to TLR2-mediated induction of 
β-defensin-2 (Birchler et al., 2001). Moreover, TLRs are involved in 
infection-induced cell death, which may limit the spread of pathogens by localizing 
cell death at the site of pathogen invasion. Several microbial components such as LPS 
(Zychlinsky et al., 1992) and lipoprotein (Aliprantis et al., 1999) trigger apoptosis of 
macrophages and endothelial cells.  
 
On the other hand, TLRs also play crucial roles in the control of adaptive immunity 
development. Signals of TLRs for the activation of adaptive immunity are largely 
mediated by APCs, especially DCs. ImDCs in the periphery have a high capacity of 
endocytosis, which facilitates antigen uptake. They are activated by various microbial 
components, including LPS (Szmania et al., 2001), CpG DNA (Hemmi et al., 2000), 
PGN (Michelsen et al., 2001) and lipoprotein (Hertz et al., 2001) and the cell wall 
skeleton of Mycobacteria (Tsuji et al., 2000), to undergo maturation. Once matured, 
DCs lose the ability to endocytose pathogens and migrate into the draining lymph 
nodes where they present the captured antigens to naïve T cells. This initiates 
antigen-specific adaptive immunity.  
 
The involvement of TLRs in the regulation of adaptive immune responses was 
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demonstrated in vivo using MyD88-/- mice. MyD88-/- mice exhibited defective 
production of IFN-γ from CD4+ T cells and Ag-specific IgG2a when immunized with 
Ag mixed with complete Freund’s adjuvant (Schnare et al., 2001; Watanabe et al., 
2002). These mice also had diminished Th1 immune response against a protozoan 
parasite (Jankovic et al., 2002).  
 
1.4 Phagocytic receptors 
Phagocytosis, the process by which cells internalize large particles, is a classic model 
of microbe-innate immune cell interactions and an essential component of innate 
immunity (Stossel, 1999). It is accompanied by intracellular signals that trigger 
cellular processes as diverse as cytoskeletal rearrangement, alterations in membrane 
trafficking, activation of microbial killing mechanisms, production of pro- and 
anti-inflammatory cytokines and chemokines, activation of apoptosis, and production 
of molecules required for efficient antigen presentation to the adaptive immune 
system (Greenberg, 1999; Underhill et al., 1999a) (Fig. 1.6). Phagocytes, such as 
macrophages and DCs, express a broad spectrum of receptors to bind and internalize 
microbes (Underhill and Ozinsky, 2002) (Table 1.4). Some of these receptors are 
PRRs, while others are receptors for opsonized microbes (Underhill and Ozinsky, 






Table 1.4 Phagocytic receptors for microbes (Underhill and Ozinsky, 2002) 
Receptors Ligands 
Fc Receptors  
  FcγRI (CD64) IgG-, CRP-, SAP-opsonized particles 
  FcγRII(CD32) IgG-, CRP-, SAP-opsonized particles 
  FcγRIII (CD16) IgG-, CRP-, SAP-opsonized particles 
  FcεRI IgE-opsonized particles 
  FcεRII (CD23) IgE-opsonized particles 
  FcαRI (CD89) IgA-opsonized particles 
Complement Receptors  
  CR1 (CD35) MBL-, C1q-, C4b-, C3b-opsonized particles 
  CR3 (αMβ2, CD11b/CD18, Mac1) iC3b-opsonized particles 
  CR4 (αXβ2, CD11c/CD18, gp150/95) iC3b-opsonized particles 
Intergrins  
  α5β1 (CD49e/CD29) Fibronectin/Vitronectin-opsonized particles 
  α4β1 (CD49d/CD29)  
  αvβ3 (CD51/CD61)  
Scavenger Receptors  
  SRA Bacteria, LPS, Lipoteichoic Acid 
  MARCO Bacteria 
Mannose receptor (CD206) Mannan 
Dectin-1 β1,3-glucan 
CD14 LPS, peptidoglycan, 
C1qR(P) C1q, MBL, SP-A 
(MACO: macrophage receptor with collagenous structure) 
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Figure 1.6 Receptor and signaling interactions during phagocytosis of microbes 
Multiple receptors simultaneously recognize microbes both through direct binding 
and by binding to opsonins on the microbe surface. Receptor engagement induces 
many intracellular signals, and several molecules are utilized in many pathways. 
Signaling during phagocytosis may subsequently serve to activate or inhibit further 
phagocytosis and microbe-induced responses. Many pathogenic microbes actively 




Fc receptors (FcR) are found on essentially all leukocytes. Many effector functions of 
immunoglobulins or antibodies (Abs) are mediated by interaction of the constant 
region (Fc) of immunoglobulins with FcRs. Specific FcRs exist for all classes of 
immunoglobulins: FcαR for IgA, FcδR for IgD, FcεR for IgE, Fcα/µR for IgA and 
IgM and FcγRI, FcγRII and FcγRIII for IgG.  
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Fc receptors for IgG (FcγR) were initially identified with the observation that IgG 
antibodies could be directly cytophilic for macrophages when presented as opsonized 
RBCs (Berken and Benacerraf, 1966). The binding of IgG antibodies to macrophages 
was independent of the antigen binding regions (the Fab fragments) of the antibodies 
and required only the Fc fragments. In mammals, four different classes of FcγRs have 
been defined: FcγRI (CD64), FcγRII (CD32), FcγRIII (CD16), and FcγRIV 
(Nimmerjahn and Ravetch, 2006).  
 
FcγRI, II and III have been intensively studied in human and mouse. In mouse, each 
class is encoded by a single gene. However, in human a total of eight genes have been 
identified: three genes for FcγRI (A, B, C), three for FcγRII (A, B, C) and two for 
FcγRIII (A, B) (Table 1.5). The FcγR genes are derived from a common ancestral 
gene and are structurally related. They contain conserved Ig-like extracellular 
domains and divergent transmembrane and cytoplasmic regions (Qiu et al., 1990) (Fig. 
1.7). FcγRI and FcγRIII are expressed as multimeric receptor complexes composed of 
a receptor-specific antibody-binding FcRα chain associated with common FcRγ and 
/or ζ  chains responsible for signaling. In contrast, FcγRII is a single-chain receptor 
with the signaling motif being part of its cytoplasmic domain (Ravetch et al., 1986). 
Whereas FcγRI displays high affinity for the antibody Fc region with restricted 
isotype specificity, FcγRII and FcγRIII have low affinity for the Fc region but a 
broader isotype binding pattern (Hulett and Hogarth, 1994; Ravetch and Kinet, 1991). 
Crosslinking of these receptors triggers a wide array of effector responses such as 
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macrophage phagocytosis (Anderson et al., 1990), NK cell Ab-dependent 
cell-mediated cytotoxicity (ADCC) (Titus et al., 1987), neutrophil activation (Chan 
and Sinclair, 1971), and the paradoxical inhibition of B cell activation (Phillips and 
Parker, 1983). A schematic diagram is presented to summarize the mechanism of 
antibody-mediated inflammation (Fig. 1.8). Details about each FcγR will be discussed 





Figure 1.7 Structural diversity and heterogeneity of human FcγRs All receptors 
belong to the Ig super family, with their extracellular regions (ECs) composed of 
disulfide (S–S)-bonded domains. FcγRI, FcγRIIa and FcγRIIIa are activating 
receptors, characterized by the presence of an immunoreceptor tyrosine-based 
activation motif (ITAM) in the cytoplasmic domain of the receptor (FcγRIIa) or 
associated with the receptor as an accessory signaling subunit (γ and/or ζ chains 
associated with FcγRI and FcγRIIIa). FcγRIIb is an inhibitory receptor, containing an 
immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic domain. 
FcγRIIIb is linked to the plasma membrane by a glycosyl phosphatidylinositol (GPI) 
anchor. Functional polymorphisms in FcγRIIa, FcγRIIIa and FcγRIIIb are indicated 
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Figure 1.8 Mechanisms of antibody-mediated inflammation Antigen−antibody 
immune complex formation results in complement activation, opsonization of target 
cells, assembly of membrane attack complexes and release of complement activators 
for chemotaxis. Fc receptor mediated cell activation triggers cellular responses, such 
as phagocytosis, antibody-dependent cellular cytotoxicity (ADCC) and release of 
inflammatory mediators (Tan Sardjono et al., 2003).
 
 
FcγRIV is a recently identified mouse activation FcγR, which has been mapped to the 
75 kb genomic interval between FcγRII and FcγRIII (Nimmerjahn et al., 2005). It 
binds to IgG2a and IgG2b antibody isotypes with intermediate affinity. The surface 
expression of FcγRIV is γ chain dependent and restricted to myeloid lineage cells. 
Blocking FcγRIV function in vivo greatly impairs the pathogenic effects of IgG2a and 




1.4.1.3 Signal transduction via FcγRs 
FcγRs can be classified into two groups based on cytoplasmic signaling motifs: (i) 
activating receptors that contain a cytoplasmic ITAM (immunoreceptor tyrosine-based 
activation motif) sequence, and (ii) inhibitory receptors that contain an ITIM 
(immunorecptor tyrosine-based inhibitory motif) sequence. The conserved ITAM 
motif is D/EX7D/EX2YX2L/IX7YX2L/I (where X is an unspecified amino acid) 
whereas the consensus ITIM motif is defined as I/V/L/SXYXXL/V. These motifs are 
also found in other immune receptors. For example, ITAM is found in the B cell 
receptor (BCR) Iga/Igb-chains and in the CD3 molecule of T cell receptors (TCR).  
 
Signal transduction mediated by activating FcγRs, i.e. FcγRI, FcγRIIa and FcγRIII, 
can be dissected into following steps (Kurosaki, 1999; Ravetch and Bolland, 2001) 
(Fig. 1.9): 
(i) Aggregation of the activating FcγRs by ICs leads to tyrosine phosphorylation 
of the ITAM motif by members of the Src-kinase family. This recruits Src 
homology 2 domain (SH2)-containing kinases, most notably the Syk-kinase 
family members. Depending on the particular cell type, different kinases are 
involved in these signaling pathways. For instance, FcγIIIA aggregation 
activates lck in NK cells, while FcγRIIA or FcγRIIIA activates lyn and hck in 
monocytic and mast cells. Likewise, syk is activated in mast cells and 
macrophages, whereas the related kinase ZAP70 is activated in NK cells. 
(ii) These early events result in the recruitment and activation of 
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phosphatidylinositol 3-kinase (PI3-K). This enzyme catalyzes the generation 
of phosphatidylinositol (3, 4, 5)-trisphosphate (PIP3) from a membrane 
phospholipid phosphatidylinositol (4, 5)-bisphosphate (PIP2).  
(iii) PIP3 recruits molecules containing the pleckstrin homology (PH) domain, such 
as phospholipase-Cγ (PLCγ) and Tec kinases. Myeloid cells contain several 
Tec kinases, named Btk, Itk, and Emt, that can all be activated upon FcR 
aggregation. Adaptor molecules SLP-76 and BLNK have been identified to 
link Syk activation with Btk and PLCγ responses. Activated Syk 
phosphorylates BLNK and thereby brings BLNK to the membrane fraction, 
eventually leading to co-localization of Syk, BLNK, and Btk. Phosphorylated 
BLNK also brings PLCγ into close proximity of the Syk-BLNK-Btk complex 
and thereby facilitates the tyrosine phosphorylation and subsequent activation 
of PLCγ. PLCγ cleaves PIP3 into two secondary signal messengers 
diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3).  
(iv) IP3 and DAG, generated by PLCγ activation, evoke calcium mobilization and 
PKC activation, respectively. IP3 binds IP3 receptors (IP3Rs) located in the ER, 
leading to calcium release from internal stores. In addition, it is proposed that 
sustained elevation of IP3 results in progressive depletion of ER stores, 
efficiently coupling ER store to opening of calcium channels on the plasma 
membrane. This leads to calcium influx and sustained calcium mobilization. 
(v) GTP-binding proteins, such as Ras and Rac are also activated upon FcR 
aggregation. Together with PKC, they regulate the MAPK cascades. Ras binds 
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directly to Raf-1, the MAPKKK in extracellular signal-regulated kinase (ERK) 
pathway. Stimulation of PKC with phorbol esters can also promote ERK 
activation. Unlike the ERK pathway, the Jun amino-terminal kinase (JNK) 
pathway is regulated by the small GTP-binding proteins Rac1 and Cdc42. 
Regulation of the p38 kinase is also achieved through PKC, Rac1 and Cdc42. 
And maximum p38 activation appears to require only PKC, not calcium.   
 
FcγRIIb is a single-chain receptor with the distinctive ITIM motif in its cytoplasmic 
domain. Upon co-engagement of FcγRIIb and an ITAM-bearing receptor, the ITIM 
motif is phosphorylated by the Lyn kinase (Fig. 1.10). The phosphorylated ITIM 
motif is recognized by the SH2 domain of the Src homology 2-containing inositol 
polyphosphate 5'-phosphatase (SHIP). Activated SHIP breaks down PIP3, which 
results in the release of PH domain-containing proteins, e.g. Btk and PLCγ, from the 
membrane. Therefore, influx of extracellular Ca2+ is reduced, which leads to the 
abrogation of ITAM-mediated signaling. FcγRIIb phosphorylation also perturbs the 









Figure 1.9 Cellular activation by FcgRIII aggregation This figure shows an 








Figure 1.10 Signaling pathways triggered by BCR-FcγRII co-ligation Cellular 





1.4.1.4 Genetic coding, structure and cell distribution of Human FcγRs 
FcγRI (CD64) 
Human FcγRI is represented by three highly homologous genes, FCGR1A, FCGR1B 
and FCGR1C which are mapped on chromosome 1 band q21.1 (Ravetch, 1994). 
FCGR1A encodes a glycoprotein of 72 kD containing three extracellular Ig-like 
domains involved in IgG binding. FCGR1B has two transcripts a and b. Transcript b is 
expressed in myeloid cells, but this transcript resides in the ER and therefore does not 
contribute to cell activation. For FCGR1C, it has not yet been clarified whether it 
encodes for a functional protein.  
 
FcγRI binds with high affinity (Ka=108-109M-1) to monomeric as well as aggregated 
IgG. This unique high affinity is dependent on the extra third Ig domain (Allen and 
Seed, 1989). In addition, its binding to IgG exhibits high specificity for human IgG1 
and IgG3 (van de Winkel and Capel, 1993). Association and interaction with the 
common FcRγ chain, has been shown for FcγRI (Ernst et al., 1993). The FcRγ chain is 
a 20-kD disulfide-linked homodimer, which links the ligand binding chains to 
intracellular signaling pathways (Wirthmueller et al., 1992). Although association 
with FcRγ-chain is not required for FcγRI folding and targeting to the cell membrane, 
it is critical for both FcγRI signal transduction and stable expression in vitro and in 
vivo (van Vugt et al., 1996). It also increases the binding affinity of FcγRI to 
monomeric IgG (Miller et al., 1996).  
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FcγRI is constitutively expressed on monoctyes and macrophages and can be induced 
by IFN-γ on neurophils, eosinophils and glomerular mesangial cells (Hulett and 
Hogarth, 1994; Ravetch and Kinet, 1991; Uciechowski et al., 1998; van de Winkel 
and Capel, 1993). Its expression is also induced by G-CSF on neutrophils and by 
IL-10 on mesangial cells (Kerst et al., 1993; Uciechowski et al., 1998). In human, it 
has been reported that blood CD33brightCD14-HLA-DRbrightCD83- DCs constitutively 
expressed FcγRI and FcγRII (Fanger et al., 1996). And 20-24 h IFN-γ stimulation 
significantly increased FcγRI expression in these blood DCs. However, moDCs 




FcγRII is encoded by FCGR2A, FCGR2B and FCGR2C located on human 
chromosome 1q23-24 (Ravetch, 1994). All three FCGR2 genes encode 40-kD 
glycoproteins containing two extracellular Ig-like domains.  
 
FcγRII binds IgG in the form of ICs (Ka=107M-1) with a specificity for humen IgG1 
and IgG3 (van de Winkel and Capel, 1993). It is the only FcγR known that contains 
both extracellular IgG-like domains and cytoplasmic ITAM or ITIM domains in a 
single polypeptide. Several isoforms of FcγRII exist, which are highly homologous in 
their extracellular and transmembrane regions but differ in their cytoplasmic domains. 
FcγRIIa and FcγRIIc contain ITAM motifs and are therefore activating receptors, 
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whereas FcγRIIb contains an ITIM motif and is thus an inhibitory receptor (Ravetch 
and Kinet, 1991).  
 
Of the FcγRs, FcγRII is most widely expressed. They are present on almost all human 
leucocytes, including neutrophils, eosinophils, basophils, monocytes macrophages, 
platelet, LCs, B cells and some T-cell subsets (Hulett and Hogarth, 1994; Ravetch and 
Kinet, 1991; van de Winkel and Capel, 1993) . On basophils, platelets, LCs, placental 
endothelial cells and B cells, FcγRII is the sole FcR. Several inflammatory mediators 
have been shown to influence FcγRII expression level. GM-CSF and IFN-γ 
up-regulate FcγRIIa expression on eosinophils (Koenderman et al., 1993; Rudge et al., 
2002). IL-4 down-regulates FcγRIIb expression on B cells (Rudge et al., 2002) while 
it up-regulates FcγRIIb on monocytic cells (Tridandapani et al., 2002).  
 
FcγRIII (CD16) 
Human FcγRIII is encoded by two genes FCGR3A and FCGR3B, both located on 
chromosome 1q23-24 (Ravetch, 1994). Both gene products are heterogeneous in size 
as a result of variable N-linked glycosylation, with molecular masses between 50-80 
kD. FCGR3A and FCGR3B encode for proteins with two extracellular Ig-like 
domains. While FcγRIIIa is a typical type I receptor, FcγRIIIb does not contain a 
transmembrane domain or a cytoplasmatic tail and is anchored to the cell membrane 
via a glycosylphosphatidylinositol (GPI) anchor (Huizinga et al., 1988; Selvaraj et al., 
1988; Simmons and Seed, 1988).  
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 FcγRIII binds IgG in the form of ICs, with specificity for human IgG1 and IgG3 
(Ravetch and Kinet, 1991; van de Winkel and Capel, 1993). Unlike FcγRI, FcγRIIIa is 
critically dependent on the FcRγ chain and/or the CD3 ζ-chain for efficient surface 
expression, because it contains an ER retention signal (Kurosaki et al., 1991).  
 
FcγRIIIa is constitutively expressed on macrophages, NK (Uciechowski et al., 1992), 
and γδ T cells  and can be induced by IFN-γ on glomerular mesangial cells(Radeke 
et al., 1994). FcγRIIIa can be induced by TGF-β on monocytes (Wahl et al., 1992). In 
contrast, IL-4 strongly reduces FcγRIIIa expression on these cells (Wong et al., 1991). 
FcγRIIIb is the most abundant receptor on neutrophils and can be induced by IFN-γ 
on eosiophils (Hartnell et al., 1992). 
 
1.4.1.5 Functions of FcγRs 
FcγRI and III   
FcγRI mediates multiple biological functions upon ligation, including phagocytosis of 
opsonized erythrocytes (Anderson et al., 1990), internalization of small ICs (Fanger et 
al., 1989; Graziano and Fanger, 1987; Harrison et al., 1994), killing of opsonized 
cellular targets via ADCC (Graziano and Fanger, 1987), cytokine release (Debets et 
al., 1990; Krutmann et al., 1990) and superoxide production (Pfefferkorn and Fanger, 
1989a; Pfefferkorn and Fanger, 1989b; Shen et al., 1986).  
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And the role of FcγRIII is associated with clearance of ICs and mediation of ADCC. 
On human NK cells, upon ligand binding, FcγRIII induces transcription of interleukin 
2 receptor (IL-2R) and production of IFN-γ and TNF-α (Anegon et al., 1988) and 
enhances adhesion of NK cells to laminin (Gismondi et al., 1992).  
 
Macrophages from the FcRγ chain-/- mice, lacking FcγRI, FcRγRIII and FcεR, are 
unable to phagocytose IgG-opsonized particles (Takai et al., 1994). These mice also 
exhibit a defective NK cell-mediated ADCC and mast cell-mediated allergic response. 
FcRγ has also been shown to play a major role in IC-driven inflammatory reactions, 
since FcRγ-/- mice are impaired in Arthus reaction, protected from fatal 
glomerulonephritis (Sylvestre and Ravetch, 1994). Furthermore, cytotoxic Abs trigger 
inflammation through FcRγ, since γ chain-/- mice are protected form experimental 
immune hemolytic anemia and experimental immune thrombocytopenia (Clynes and 
Ravetch, 1995).  
 
To be able to distinguish between the functions of the two activating receptors, 
FcγRI-/- and FcγRIII-/- mice lacking exclusively FcγRI or FcγRIII have been generated. 
FcγRI-/- mice show impaired hypersensitivity responses, strongly reduced cartilage 
destruction in an arthritis model, and impaired protection from a bacterial infection 
(Ioan-Facsinay et al., 2002). In addition, it results in a wide range of defects in 
antibody Fc-dependent functions, including (i) loss of uptake of ICs of the T 
cell-independent immunoglobulin IgG3, as well as a profound reduction in IgG2a 
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uptake; (ii) reduction in macrophages-mediated ADCC; (iii) impaired IC-dependent 
antigen presentation to T cells; (iii) decreased IC-induced inflammation; and (iv) 
enhancement of antibody responses (Barnes et al., 2002). 
 
FcγRIII-/- mice lack NK cell-mediated antibody-dependent cytotoxicity and 
phagocytosis of IgG1-coated particles by macrophages. And these mice lack 
IgG-mediated mast cell degranulation, are resistant to IgG-dependent passive 
cutaneous anaphylaxis, and exhibit an impaired Arthus reaction (Hazenbos et al., 
1996). 
 
FcγRII   
FcγRIIa has several features that are unique: (i) it is only found in humans; (ii) it 
forms a noncovalent homodimer (Maxwell et al., 1999); and (iii) it transduces 
signaling by several other FcγRs, such as FcγRIIIb in neutrophiles (Chuang et al., 
2000). Therefore, FcγR signaling, at least in some cases, is ‘focused’ through FcγRIIa. 
FcγRIIa has been shown to have very similar biological functions as FcγRI. Studies 
on transgenic mice that express human FcγRIIa have provided valuable data on the 
functional properties of this receptor (Tan Sardjono et al., 2005). These mice are 
profoundly sensitive to antibody-induced inflammation. And the transgenic 
expression of FcγRIIa renders genetically resistant mice susceptible to 
collagen-induced arthritis (CIA). This finding challeges the traditional concept that, 
antibody is of relatively minor importance in this disease model. Most interestingly, 
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the FcγRIIa transgenic mice also develop a spontaneous autoimmune syndrome with 
features similar to rheumatoid arthritis, systemic lupus erythematosus, pneumonitis 
and non-erosive arthritis. Taken together these data imply that, even in the presence of 
endogenous FcγRs, FcγRIIa remains a potent activator of inflammation.  
 
FcγRIIb is an important regulator in the signaling of activating FcγRs. When 
co-ligated with BCR, it triggers SHIP-dependent inhibition of B cell activation and 
SHIP-independent control of proliferation (Bolland and Ravetch, 1999). Besides, 
crosslinking of FcγRIIb on B cells without BCR activation leads to B cell apoptosis 
(Pearse et al., 1999; Tzeng et al., 2005). FcγRIIb may also play an important role in 
regulating immunity and tolerance through DCs. FcγRIIb expression on DCs controls 
IC-mediated DC maturation, as DCs derived from FcγRIIb-/-mice show an enhanced 
potential to generate antigen-specific T cell responses in vitro and in vivo (Kalergis 
and Ravetch, 2002). Furthermore, incubation of human DCs with an FcγRIIb blocking 
antibody is sufficient to induce DC maturation by ICs normally present in plasma 
(Boruchov et al., 2005; Dhodapkar et al., 2005). In addition to its autoregulatory role 
in the afferent response, FcγRIIb is also an important modulator during the efferent 
phase of an immune response. Lack of FcγRIIb leads to enhanced IC-mediated 





1.5 Pro-inflammatory cytokines 
Cytokines are proteins secreted by cells of innate and adaptive immunity in response 
to microbes and other antigens. They have immunomodulatory roles in the onset and 
regulation of inflammation and in the activation and differentiation of T cells 
(Henderson et al., 1996; Luster, 2002). TNF-α, IL-1 and IL-6 are major cytokines 
involved in the regulation of inflammatory reactions. These cytokines can induce 
fever and acute phage response with the production of complement, CRP, 
ceruloplasimin and metallothionine, etc. They also enhance the epithelial response to 
the pathogen and induce expression of adhesion molecules on vascular endothelium in 
favor of the diapedesis of phagocytes (Basset et al., 2003). In this project, we 
concentrate on IL-1, especially IL-1β. 
 
1.5.1 IL-1 
IL-1 was originally described in the 1940s as a heat-labile protein and found in acute 
granulocytic exudate fluid. When injected into animals or humans, it produced fever. 
At that time, it was called endogenous pyrogen (Atkins, 1960). Later, it has been 
found to be involved in various reactions, including inflammation, acute-phase 
responses, fever development, stress responses and certain diseases development, 
such as rheumatoid arthritis (RA) (Dinarello, 1996). Therefore, IL-1 is now regarded 




1.5.1.1 Functional properties of IL-1 
IL-1 affects nearly every cell type, and often in concert with other cytokines or small 
mediator molecules (Dinarello, 1996). IL-1 acts on monocytes and macrophages to 
induce the production of IL-1, TNF-α, IL-6, IL-8, prostaglandin E2 and nitric oxide, 
enhancing their killing activities against bacteria, protozoa and tumor cells (Dinarello, 
1991). Furthermore, it enhances CD40L-mediated cytokine secretion by human DCs 
(Luft et al., 2002). IL-1 also acts on NK cells, in collaboration with IL-2 and IFN-γ, to 
potentiate their cytotoxic activity (Dinarello, 1991). Apart from its role in 
inflammation, it has gradually become evident that this cytokine has numerous 
functions related to adaptive immunity. It has been shown that IL-1 stimulates de 
novo expression of the p55 chain of the IL-2R on CD4-8- thymocytes (Falk et al., 
1989), and up-regulates IL-2R expression on T helper type 2 (Th2) cell clones 
stimulated with B cells (Taira et al., 1993). TCR-mediated proliferation of Th2 cells 
occurs only in the additional presence of a co-stimulatory signal delivered by IL-1 
(Kurt-Jones et al., 1987). In addition, IL-1 enhances proliferation and differentiation 
of B cells synergistically with IL-4 and IL-6 (Maliszewski et al., 1990), and enhances 
T cell-dependent antibody production through induction of CD40L and OX40 on T 
cells (Nakae et al., 2001b). IL-1 and IL-4 are important mediators of B cell growth 
and differentiation. In the context of autoimmunity, IL-1 promotes CIA in mice and 




1.5.1.2 Two forms of IL-1 
There are two forms of IL-1, IL-1α and IL-1β, encoded by two distinct genes (Bensi 
et al., 1987; Clark et al., 1986). IL-1α and β are synthesized as 31-kD precursors 
without leader sequences. Processing of IL-1α or β precursors to 17-kD mature forms 
requires specific cellular proteases (Dinarello, 1991). Despite sharing less than 30% 
sequence identity, these two cytokine products exert similar, but not completely 
overlapping biological activities through the shared receptor IL-1 type I recptor 
(IL-1RI) (Dinarello, 1997). Although a type II IL-1R has also been found, this 
receptor is not considered to be involved in the signal transduction, but is believed to 
play a regulatory role as a ‘decoy’ receptor (Colotta et al., 1994). The two forms of 
IL-1 share several similarities: (i) the mature forms of IL-1α and β assume similar 
three dimensional structures of all β sheets; (ii) both molecules are translated in the 
cytosol associated with cytoskeletal rather than ER structures; (iii) both protein 
precursors undergo myristoylation on lysine residues in their respective pro-forms. 
However, differences between IL-1α and IL-β are also remarkable. It has been 
reported that in human blood mononuclear cells stimulated with LPS or TNF, the rate 
of IL-1β transcription was greater than that of IL-1α. In these activated cells, IL-1β 
mRNA was the predominant IL-1 mRNA species and remained elevated longer than 
IL-1α mRNA, probably due to higher mRNA stability (Turner et al., 1989). 
Furthermore, pro-IL-1α is fully active and able to bind to the IL-1R without further 
proteolytic processing. By contrast, pro-IL-1β must be processed in order to bind to 
IL-1R and exert biological activity (Mosley et al., 1987). While pro-IL-1α can 
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associate with the plasma membrane via a lectin-like interaction and exist a 
membrane form, pro-IL-1β has no membrane form (Brody and Durum, 1989). In 
addition, pro-IL-1β is cleaved by caspase-1, a cysteine protease (Black et al., 1988; 
Kostura et al., 1989) , whereas pro-IL-1α is processed by calpain, a calcium-activated 
neutral protease (Kobayashi et al., 1990).Finally, increasing efforts have been made to 
precisely distinguish their functional differences. It has been reported that IL-1β, but 
not IL-1α, is required for antigen-specific T cell activation (Nambu et al., 2006) and T 
cell-dependent antibody production (Nakae et al., 2001a).  
 
1.5.2 IL-1β 
The primary sources of IL-1β are the blood monocytes, tissue macrophages and 
dendritic cells (Dinarello, 1991). B lymphocytes and NK cells also express IL-1β. 
Keratinocytes produce IL-1β under inflammatory conditions. In health, the circulating 
human blood monocyte or bone marrow aspirate does not constitutively express 
IL-1β . 
 
IL-1 is a highly inflammatory cytokine and the margin between clinical benefits and 
unacceptable toxicity in humans is exceedingly narrow. Hence, there is growing 
evidence that the production and activity of IL-1, particularly IL-1β, are tightly 
regulated (Dinarello, 1996). The regulation of IL-1β production occurs at multiple 




Figure 1.11 Steps in the processing and secretion of IL-1β (A) TLR ligands such as 
endotoxin trigger gene expression and synthesis of the IL-1ß precursor, which 
remains diffusely in the cytosol. In the same cell, inactive procaspase-1 is bound to 
components of the IL-1ß inflammasome, which contains the products of the NALP-3 
gene. The IL-1ß inflammasome is kept in an inactive state by binding to a large 
molecular weight putative inhibitor. (B) After TLR signals, there is a transient 
uncoupling of the inhibitor and NALP-3 gene products from procaspase-1, which then 
colocalizes with the IL-1ß in secretory lysosomes. (C) Activation of the nucleotide 
receptor P2X7 by ATP or LL37 initiates the efflux of potassium from the cell via a 
potassium channel. The efflux of potassium activates the autocatalytic processing of 
procaspase-1. Active caspase-1 cleaves the IL-1ß precursor in an active cytokine. (D) 
The efflux of potassium ions results in the influx of calcium ions, which in turn 
activate phospholipases. Phosphatidylcholine-specific phospholipase C (PC-PLA-2) 
facilitates lysosomal exocytosis and secretion of IL-1. (Dinarello, 2005) 
 
 
1.5.2.1 Transcriptional regulation of IL-1β 
The promoter region for IL-1β contains a clear TATA box, a typical motif of inducible 
genes (Dinarello, 1996). The half-life of IL-1β mRNA depends upon the cell type and 
the conditions of stimulation. LPS triggers transient transcription and steady state 
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levels of IL-1β mRNA. The mRNA level peaks at 4 h, is sustained for another 2 to 4 h, 
and then decreases rapidly due to the synthesis of a transcriptional repressor (Fenton 
et al., 1987; Fenton et al., 1988). However, if IL-1 is used as the stimulus of its own 
gene expression, the steady state mRNA level increases slower and remains for 30 h 
(Schindler et al., 1990c). Unlike most cytokine promoters, the IL-1β gene regulatory 
regions can be found distributed over several thousand base pairs upstream and a few 
base pairs down-stream from the transcriptional start site. The IL-1β promoter 
required for transcription has two independent enhancer regions (-2782 to -2729) 
(Tsukada et al., 1994) and (-2896 to -2846) (Shirakawa et al., 1993), which appear to 
act cooperatively. The former is a composite NF-IL6-cAMP response element binding 
site (NF-IL6-CREB), which is strongly responsive to LPS, whereas the latter contains 
a cAMP response element. Proximal promoter element has been identified between 
-131 and +14 (Shirakawa et al., 1993), which contains the binding sites for the nuclear 
factor Spi-1/PU.1 (Buras et al., 1994). This promoter is required for maximal IL-1β 
gene expression. Human blood monocytes, which constitutively express Spi-1/PU.1 
are exquisitely potent for IL-1β gene expression in response to LPS (Kominato et al., 
1995).  
 
Nearly all microbial products induce IL-1β gene expression via TLRs (Dinarello, 
1996). The most common stimulus used for IL-1β transcription is LPS. The amount of 
LPS that is able to induce IL-1β transcription and translation is approximately 5 
molecules per monocytes (Dinarello, 1991). It has been reported that CD40 
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engagement mediates IL-1β gene expression in both macrophages (Wagner et al., 
1994) and DCs (Gardella et al., 2000). Stimulants such as the complement component 
C5a (Schindler et al., 1990b), hypoxia, adherence to surfaces (Schindler et al., 1990a), 
or clotting of blood induce the synthesis of large amounts of IL-1β mRNA in 
monocytic cells without significant translation into the IL-1β protein. In these cases, 
although the IL-1β mRNA assembles into large polyribosomes, there is little 
significant elongation of the peptide (Kaspar and Gehrke, 1994). This dissociation 
between transcription and translation is characteristic of IL-1β but also of TNF-α 
(Dinarello, 1996). 
 
1.5.2.2 Translational regulation of IL-1β 
Studies on cytokine suppressing anti-inflammatory drugs (CSAIDs) reveal that the 
reduction of IL-1 and TNF translation caused by these compounds are due to the 
inactivation of a MAPK (Lee et al., 1994). This CSAID-associated MAPK apparently 
phosphorylates proteins that are required for translation of cytokine mRNA into their 
respective proteins. It shares homology with that of the yeast hyperosmolarity 
glycerol-1 gene (HOG-1), and is identical to human p38 MAPK that is 
phosphorylated in cells stimulated with LPS (Han et al., 1994; Han et al., 1995). And 
this MAPK is also phosplorylated upon IL-1 stimulation (Freshney et al., 1994). It has 
been reported that initiation factor eIF-4E requires a MAPK-mediated 
phosphorylation step to dissociate from a translational regulatory molecule (Lin et al., 
1994). Therefore, p38 MAPK seems to modulate IL-1β translation.  
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1.5.2.3 Post-translational cleavage of IL-1β 
After synthesis, 31-kD pro-IL-1β remains primarily cytosolic until it is cleaved and 
secreted. Some pro-IL-1β is found in lysosomes (Bakouche et al., 1987) or associated 
with microtubules (Stevenson et al., 1992). Either localization may play a role in 
IL-1β secretion (Dinarello, 1996).  
 
Pro-IL-1β was initially found to be cleaved by a protease so as to generate the mature 
secretory IL-1β protein (mIL-1β) (Black et al., 1988). This protease was later 
identified as a cysteine protease and termed IL-1β-converting enzyme (ICE) and it is 
also known as caspase-1 (Thornberry et al., 1992). Caspase-1 cleaves the 31-kD 
pro-IL-1β at Asp116-Ala117, to generate the C-terminal 17.5-kD bioactive fragment. 
It also cleaves pro-IL-1β at Asp27-Gly28 to yield a product of 28-kD, whose 
physiologic function is presently not understood. The requirement for caspase-1 in 
IL-1β processing was confirmed using caspase-1-/- mice (Kuida et al., 1995). These 
mice are defective to process pro-IL-1β into bioactive IL-1β and are resistant to the 
lethal effect of LPS. 
 
Caspase-1 is constitutively expressed by cells, such as monocytic cells. The major 
form of caspase-1 is a 45-kD inactive precursor protein (p45) found in the cytoplasm 
(Ayala et al., 1994). Active caspase-1 is a heterodimer, comprised of one 10-kD (p10) 
chain and one 20-kD (p20) chain (Miller et al., 1993). The p10 chain is essential for 
caspase-1 activity, while the p20 is the catalytic subunit. Caspase-1 itself contributes 
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to the auto-processing of its precursor by undergoing oligomerization with itself or its 
homologs. It has been shown that LPS activates caspase-1 in cultured monocytic and 
endothelial cells. Furthermore, IL-4 and Janus kinase 3 down-regulates LPS-induced 
caspase-1 activation (Kim et al., 2004).  
 
In addition to caspase-1, pro-IL-1β can be cleaved by bacterial proteases (Kapur et al., 
1993), chymotrypsin (Hazuda et al., 1990), as well as the physiologically more 
relevant enzymes, such as leukocyte elastase (Black et al., 1988), granzyme A (Irmler 
et al., 1995), and a variety of proteases commonly found in inflammatory fluids. 
Except for granzyme A, all of these proteases cleave the pro-IL-1β into a C-terminal 
active fragment larger than 18-kD. Some matrix metalloproteases (MMPs) commonly 
found in joint fluids from patients with RA also cleave pro-IL-1β into bioactive IL-1β. 
These include gelatinase-B, MMP-2, MMP-3 and MMP-9 (Schonbeck et al., 1998).  
 
1.5.2.4 Secretion of IL-1β 
IL-1β is unique among cytokines, because it is not secreted via the classical exocytic 
pathway (Rubartelli et al., 1990). The lack of a secretory signal peptide hampers its 
targeting to the ER. Exocytosis of endolysosome-related vesicles has been suggested 
as a possible secretory route for IL-1β (Andrei et al., 1999). Release of IL-1β from 
monocytes or macrophages is an inefficient process (Hogquist et al., 1991). Optimal 
IL-1β secretion requires additional stimuli, including ATP (Perregaux et al., 1996a), 
cytolytic T-cells (Perregaux et al., 1996b), bacterial toxins (Bhakdi et al., 1990) , and 
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K+ ionophores (Perregaux et al., 1992). While ATP at concentrations ≥ 2 mM 
promoted rapid mature IL-1β release from LPS-stimulate monocytes and 
macrophages, blocking anion transport reduces the secretion (Laliberte et al., 1994).  
 
A purinergic receptor, designated P2X7R, has been proposed to be involved in 
ATP-trigged IL-1β release (Ferrari et al., 1997; Surprenant et al., 1996). The P2X7R is 
a member of the P2X family of nucleotide-gated channels. It is a 595-aa polypeptide 
with two membrane-spanning domains and intracellular N- and C-terminal domains 
(Surprenant et al., 1996; Wiley and Dubyak, 1989). P2X7R is predominantly 
expressed by monocytic cells such as monocytes, macrophages, as well as DCs (Collo 
et al., 1997; Mutini et al., 1999). Activation of P2X7R by ATP opens a cation-selective 
channel allowing calcium and ethidium influx, and potassium efflux (Georgiou et al., 
2005; Surprenant et al., 1996). A monoclonal antibody to the receptor suppresses the 
ATP-induced IL-1β secretion by human monocytic THP-1 cells (Buell et al., 1998). 
Moreover, P2X7R -/- mice displays altered cytokine production (Solle et al., 2001). In 
vitro, in response to ATP, pro-IL-1β in LPS-primed P2X7R-/- macrophages is neither 
processed by caspase-1 nor secreted. In vivo, subsequent ATP injection to LPS-primed 
P2X7R-/- mice fails to promote an increase in IL-1 production as compared with wild 
type mice. In addition to ATP, the human cathelicidin-derived peptide LL37 has been 
reported as a novel P2X7R activator (Elssner et al., 2004). LL37 is the bioactive C 
terminus of human cationic peptide 18 (hCAP18) (Zasloff, 2002). LL37 has been 
shown to exert antimicrobial activity toward both Gram-negative and Gram-positive 
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bacteria, to neutralize LPS, and to have chemotactic activity for neutrophils, 
monocytes, and T cells (Bals et al., 1998; Larrick et al., 1995). Its precursor hCAP18 
is found in neutrophils, in cells of the bone marrow, and in epithelial cells. LL37 
induces IL-1β processing and release in human monocytes (Elssner et al., 2004). 
 
1.6 Aims of the study 
The aim of this thesis is to study on: 
(i) IL-1β production by human moDCs  
IL-1β is a major pro-inflammatory cytokine in innate immunity, mainly produced by 
activated mononuclear phagocytes in response to bacterial products. Its unique 
stringent regulation has attracted intensive efforts to elucidate the underlying 
mechanism. Most of these studies are performed in monocytes and macrophages. Few 
have been reported in DCs. However, there is increasing evidence indicating a role for 
IL-1β in antigen-specific immunity as well as in the pathogenesis of autoimmune 
disease, and DCs are central to the outcome of IL-1β effects. Therefore, in this study, 
we investigate IL-1β production in human moDCs. 
 
(ii) The role of FcγR in the modulation of IL-1β production 
DCs employ a broad spectrum of surface receptors for pathogen detection and antigen 
capture. In physiologic or pathologic context, these receptors interplay with each 
other in order to finely modulate the immune outcome. FcγRs provide communication 
between humoral and cellular immune responses and are crucial for the regulation of 
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the immune system. It has been shown that FcγR activation on macrophages and DCs 
modulates TLR signaling. In vitro, FcγR ligation on macrophages results in reduced 
IL-12 production and increased IL-10 production in response to LPS. However, it 
remains unknown whether FcγR activation plays a role in IL-1β production. Thus, we 
would like to investigate the regulatory role of FcγR in TLR-mediated IL-1β 
production by human moDCs.  
 
(iii) Signaling molecules involved in IL-1β regulation 
The signaling regulation underlying the tight control of IL-1β production is not fully 
understood. To address this question, a panel of classic protein kinase inhibitors are 
applied to identify essential signal transducing molecules that either up-regulate or 













CHAPTER 2 MATERIALS AND METHODS 
2.1 Molecular Biology 
2.1.1 Materials 
2.1.1.1 DNA primer synthesis 
Primers for polymerase chain reactions (PCR) performed in this project are listed in 
Table 2.1. They were synthesized by Research Biolabs (Singapore). 
 
Table 2.1 Primers used in this study 
Primers Sequence (5’-3’) Expected product length (bp) 
IL-1β F GGGCCTCAAGGAAAAGAATC 205 
IL-1β R TTCTGCTTGAGAGGTGCTGA  
β-actin F GGCGTGATGGTGGGCATG 680 
β-actin R GGAAGGAAGGCTGGAAGA  
P2X7R F TCTGCAAGATGTCAAGGGC 495 
P2X7R R TCACTCTTCGGA AACTCTTTCC  
 
2.1.2 Methods 
2.1.2.1 Manipulation of RNA 
2.1.2.1.1 Isolation of total RNA from cell culture 
Total RNA was isolated using the TRIZOL Reagent (Gibco BRL), according to the 
manufacturer’s instructions. Briefly, 2×106 cells were lysed in 1 ml of TRIZOL 
Reagent. The lysate was incubated for 5 min at room temperature to allow complete 
dissociation of nucleoprotein complexes. 0.2 ml of chloroform was added to the lysate 
and vigorously mixed for 15 sec. After 2 min for phase separation, it was centrifuged 
at 4 °C for 15 min at 12,000 rpm. The aqueous phase was transferred to a fresh tube. 
To precipitate the RNA, 0.5 ml of isopropyl alcohol was added and incubated for 10 
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min at room temperature. RNA was pelleted by centrifugation for 10 min at 12,000 
rpm and washed with 1 ml 75% (v/v) ethanol, air-dried. The purified RNA was 
dissolved in 20 µl of Diethyl Pyrocarbonate (DEPC)-treated water and stored at -80°C. 
DEPC was obtained from Sigma.  
 
2.1.2.1.2 Quantitation of RNA 
2 µl of RNA sample was diluted in 0.5 ml of DEPC-treated water and optical density 
was measured at 260 nm using a DU® 640B spectrophotometer (Beckman). RNA 
concentration was estimated according to the following formula:  
1OD260 = 40 µg/ml. Absorption at 280 nm was also taken, and the ratio of 
OD260/OD280 was used to determine RNA purity. Samples with the OD260/OD280 ratio 
greater than 1.7 were used.  
 
2.1.2.1.3 Reverse transcription 
Reverse transcription was performed using the Advantage RT-for-PCR Kit (Clontech), 
according to the manufacturer’s instructions. Briefly, RNA (0.2-1.0 µg) was mixed 
with 1 µl random hexamers primer and 1 µl oligo (dT) 18 primer. The samples were 
denatured for 2 min at 70°C and rapidly chilled on ice to prevent re-annealing. 
Reverse-transcription was carried out for 1 h at 42°C in a 20 µl reaction volume 
(Table 2.2). The reaction was terminated by heating at 94°C for 5 min and cDNA can 
be used immediately or stored at -70°C.  
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 Table 2.2 Reverse transcription reaction mixture (20 µl) 
Reagent Volume (µl) Final concentration/ amount 
RNA+ DEPC-H20 12.5 0.2-1.0 µg total RNA 
Random hexamer primer 1 20 pmol 
Oligo (dT)18 primer 1 20 pmol 
5× reaction buffer 4 50 mM Tris-HCl (PH 8.3) 
75 mM KCl 
3 mM MgCl2
dNTP mix (10 mM each) 1 0.5 mM each 
RNase inhibitor 0.5 1unit/µl 
MMLV reverse trancriptase 1 ≥200 units/µg RNA  
MMLV: moloney murine leukaemia virus 
 
2.1.2.2 PCR 
PCR was performed in a 50 µl reaction volume containing 10 mM Tris-HCl (pH 8.8), 
1.5 mM MgCl2, 50 mM KCl, 0.1% (v/v) Triton X-100, 200 µM of each dNTP, 0.5 
µM each of the forward and reverse primers and 1.25 U of Taq DNA polymerase 
(Promega). Thermal cycling was carried out in a DNA thermal cycler (MJ Research) 
as follows: (i) 1 cycle of 94°C (initial DNA denaturation) 1 min; (ii) 30 cycles of 
94°C (DNA denaturation) 30 sec, 52-68°C (primer annealing) 30 sec, 72°C (extension) 
1-3 min; and (iii) a final cycle of 72°C (extension) for 10 min. Annealing temperature 
was calculated using 4°C for every C or G base, and 2°C  for every A or T base. 
Extension time was estimated using 1 min for every 1 kb of DNA amplified. The PCR 




2.1.2.3 Electrophoresis of nucleic acids 
The separation of DNA products was carried out by agarose gel electrophoresis 
(Sambrook et al, 1989). Agarose was dissolved in Tris-acetate-EDTA (TAE) buffer 
(Appendix) at a concentration of 1% (w/v) and boiled in the microwave for 1 min. 
After the melted agarose is cooled down to approximately 60°C, ethidium bromide 
(10,000 µg/ml) (Bio-Rad) was added to a final concentration of 0.5 µg/ml. The 
agarose was then casted in a gel casting set (Bio-Rad), avoiding bubbles. DNA 
samples were mixed with 5×sample loading buffer (Appendix) and loaded to the gels 
together with 1 Kb Plus DNA Size Standard (Gibco BRL). Electrophoresis was 
carried out at 100 V in TAE buffer and stopped when the dye front reached 3/4 of the 
gels. Ethidium bromide chelates DNA to produce fluorescence signal upon UV 
illumination. Results were recorded by UV-VIS sepectrophotometer (Shimadzu). 
 
2.1.2.4 Real-time PCR 
Real-time PCR was performed on a LightCycler Instrument (Roche Diagnostics 
GmgH) using LightCycler® FastStart DNA Master SYBR Green I Kit (Roche 
Diagnostics GmbH). The reaction was conducted in a total volume of 10 µl (Table 
2.3).  The LightCycler protocol for IL-1β (target gene) and β-actin (reference gene) 
quantification contained the following program: (i) 1 cycle of pre-incubation at 95°C 
10 min (activation of FastStart DNA polymerase and DNA denaturation); (ii) 45 
cycles of amplification consisting of 10 sec at 95°C (denaturation), 10 sec at 60°C 
(annealing) and 1 min at 72°C (extension); (iii) 1 cycle of melting curve containing 0 
 61
sec at 95°C (denaturaion), 15 sec at 65°C (annealing) and 0 sec 95°C (melting); and 
(iv) 1 cycle of cooling at 40°C 30 sec. The specificity of the amplified PCR product 
was assessed by a melting curve analysis. For each experiment, a negative control 
without DNA template and serial 10-fold dilutions of a standard sample were run 
together with unknown samples. The standard curves for target and reference genes 
were constructed by plotting crossing point cycle number versus the log of the 
standard’s concentration. The calibrator was one of the unknown samples, chosen as 
the basis for relative quantification. In the case of IL-1β mRNA quantification, 
lipoplysaccharide (LPS) stimulated cell sample was defined as calibrator. The final 
result was expressed as normalized ratio according the formula:  
          Concentration of target (sample)         Concentration of target (calibrator) 
Normalized = ⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯   :  ⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯ 
Ratio      Concerntration of reference (sample)      Concentration of reference (calibrator) 
 
 
Table 2.3 Real time PCR reaction mixture (10 µl) 
Reagent Volume (µl) Final concentration
10× LightCycler FastStart DNA Master SYBR Green 1  1× 
PCR primer 25 µM 0.2 each 0.5 µM 
MgCl2, 25 mM 1.6 4 mM 
cDNA template 1 ≤ 50 ng 







2.2 Cell Biology  
2.2.1 Materials 
2.2.1.1 Stimuli 
The stimuli used for cell activation were listed in Table 2.4.  
 
Table 2.4 Stimuli used in this study 
Stimulus Bacterial Strain Supplier Working 
concentration
Lipoplysaccharide (LPS) Escherichia Coli O5:55 Sigma-Aldrich 500 ng/ml
Peptidoglycan (PGN) Staphylococus aureus Fluka GmbH 10 µg/ml
Flagelllin S. thyphimurium InvivoGen 2 µg/ml
Bacteria  Escherichia Coli DH5α Invitrogen 10 bacteria:
1 cell
Chromatographically 





Working stocks of DH5α were kept at 4°C on LB agar plates. The bacteria were 
restreaded once a month on fresh agar plates. For long term storage, the bacteria were 
stored at -70°C in the respective culture medium containing 20% glycerol. Human 
IgG was immobilized on 96-well cell culture plates in sterile PBS, and incubated 
overnight at 4°C. Before use, plates were washed three times with sterile PBS to 
remove the unbound human IgG.  
 
2.2.1.2 Antibodies 




Table 2.5 Antibodies used in this study 
Antibody (anti-) Clone, isotype, conjugate 




Human CD14 UCHM1, mouse IgG2a, 




Human CD1a CB-T6 , mouse IgG1, 




Human CD40 BE-1, mouse IgG1, 




Human MHCII TDR31.1, mouse IgG1, 




Human CD16 3G8, mouse IgG1,  




Isotype control MOPC 31C, mouse IgG1, 




Isotype control RPC 5, mouse IgG2a, 




Human CD32 AT-10, mouse IgG1, 





Human CD64 10.1, mouse IgG1, 





Isotype control *sc-2866, Mouse IgG1, 





















































* denotes catalog number. 
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2.2.1.3 Pharmacological inhibitors 
The molecular target and working concentration of pharmacological inhibitors used in 
this project were listed in Table 2.6. All inhibitors were purchased from Calbiochem. 
These inhibitors were dissolved in DMSO at the stock concentration indicated. These 
inhibitors or their DMSO solvent control were pre-incubated with cells 2 h prior to 
LPS or other stimulation.  
 
Table 2.6 Inhibitors used in this study 






LY 294002 Phosphatidylinositol 3-kinase (PI3-K) 
Acts on the ATP-binding site of PI3-K 
25 µM 100 mM 
Akt Inhibitor Akt 40 µM 50 mM 
Rapamycin Mammalian target of rapamycin (mTor) 
protein 
Inhibit the phosphorylation and 




SB 203580 P38 kinase 40 µM 50 mM 
PD 98059 MAP kinase kinase (MEK) 
Inhibit the activation of MAP kinase 
40 µM 50 mM 
JNK Inhibitor II c-Jun N-terminal kinase (JNK) 
Reversible inhibitor 
40 µM 50 mM 
Chelerythrine 
chloride 
Protein kinase C (PKC) 
Acts on the catalytic domain of PKC 
500 nM 12.5 mM 
NSC23766 Rac1 
Interferences Rac1 interaction with the 
Rac-specific guanine nucleotide 
exchange factor (GEF) 
100 µM 100 mM 
 
2.2.2 Methods 
2.2.2.1 Isolation of human peripheral blood monocytes 
Peripheral blood leukocytes were obtained from NUH blood Donation Centre in the 
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form of the buffy coat preparations which were derived from healthy donors. 
Monocytes were isolated from buffy coats essentially as previously described with 
minor modifications (Cao et al., 2006). Briefly, 15 ml buffy coats were diluted in 30 
ml PBS in a 50 ml tube. 30 ml diluted blood sample was loaded on 12 ml 
Ficoll-Paque (Amersham Bioscience Corp) and centrifuged for 30 min at 400 g 
without brake. Peripheral blood mononuclear cells (PBMCs) were collected from the 
gradient interface and topped up with PBS to 50 ml. PBMCs were pelleted down by 
centrifugation at 200 g, while platelets in the supernatant were removed. The washing 
step was repeated once and followed by another two rounds with the centrifugation 
speed at 100 g. The washed cells were resuspended in RPMI containing 5% (v/v) 
iron-supplemented bovine calf serum (BCS) (HyClone), splitted into three cell culture 
flasks and cultured for 2 h. 2 h later, the non-adherent cells, mainly lymphocytes, 
were removed by gently washing the adherent cells three times with 10 ml warm 
RPMI containing 5% (v/v) BCS. The adherent fraction, mainly monocytes, was 
harvested by gentle scraping. Cells were washed once with RPMI with 10% (v/v) 
BCS once before culturing in differentiation medium. Monocytes isolated by this 
method were usually 90-95% pure as judged by the expression of CD14. 
 
2.2.2.2. Generation of macrophages and DCs from monocytes 
Monocytes were plated in 6-well tissue culture plates at a density of 1×106/ml in 
complete RPMI containing 10% (v/v) BCS, 100 units/ml penicillin, 100µg/ml 
streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate, and 0.0012% (v/v) 
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2-mecaptolethanol. DCs were cultured from monocytes for 6 days in the presence of 
20 ng/ml GM-CSF and 20 ng/ml IL-4 (R&D Systems Inc). Macrophages were 
cultured from isolated monocytes for 6 days in the presence of 20 ng/ml GM-CSF. 
Every other day, half volume of the culture medium was removed and replenished by 
fresh media with differentiation cytokines. 
 
2.2.2.3 Cell activation  
Immature moDCs and macrophages were harvested, washed once with PBS and 
resuspended at 1×106/ml in RPMI containing 10% (v/v) heat-inactivated BCS, 100 
units/ml penicillin and 100 µg/ml streptomycin. BCS was heat-inactivated for 30min 
at 56°C, before added into medium. 1×105 cells in 100 µl culture medium were 
seeded in each 96-well. Immature moDCs were activated for 24h, or otherwise stated, 
with a number of microbial stimuli: 500 ng/ml LPS, 10 µg/ml PGN, 2 µg/ml flagellin 
and intact DH5α at the bacteria to cell ratio of 10 to 1. For FcγRs crosslinking, cells 
were seeded on tissue culture plates which were coated with human IgG at the 
concentration of 100 µg/ml, or other wise stated. For FcγRs blockade, moDCs were 
incubated with 10 µg/ml blocking antibodies in RPMI with 10% (v/v) heat-inactivated 
BCS at 4°C for 1 h before addition of stimuli.  
 
2.2.2.4 Flow cytometry 
Adherent cells were harvested by scrapping and combined with cells in suspension. 
Cells were washed once in FACS buffer (Appendix) and pelleted at 300 g for 5 min. 
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3×105 cells were used for each staining. For detection of cell surface proteins, cells 
were re-suspended in 50 µl cold complete RPMI and incubated with each staining 
antibody or isotype control (listed in Table 2.5) for 30 min on ice. After being washed 
twice in FACS buffer, cells were fixed in 1% (w/v) cold paraformaldehyde in PBS. 
Flow cytometry was carried out using the FACScalibur (Becton Dickinson 
Immunocytometry Systems) and total 104 cells were collected for each sample. Data 
was analysed using the WINMIDI version 2.8 software (Scripps Institute). 
 
2.2.2.5 Enzyme-linked immunosorbent assay (ELISA) 
Release of IL-1β and TNF-α into the culture medium was measured by specific 
human DuoSet ELISA Development kits, which were purchased from R&D Systems 
Inc. Assays were performed according to the manufacture’s instructions. Briefly, 
96-well BD FalconTM ELISA plates (BD Biosciences) were coated with 100 µl diluted 
capture antibodies in PBS, sealed with parafilm and incubated overnight at 4°C. The 
next day, plates were washed with 250 µl wash buffer (0.05% Tween ®20 in PBS, pH 
7.2 - 7.4) three times before blocked with 200 µl Reagent Diluent (1% BSA 5 in PBS, 
pH 7.2 - 7.4,0.2 mm filtered) for 2 h at room temperature. After plates were washed 
three times with wash buffer, 100 µl sample or standard in Reagent Diluent was added 
into each well. For some samples from stimulated cell cultures, appropriate dilution in 
Regent Diluent was made in order to keep the final reading within the linear range of 
the standard curve. Plates were sealed and incubated overnight at 4°C. On the third 
day, plates were washed three times and 100 µl of biotinylated detection antibodies 
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diluted in Reagent Diluent were added to each well. After incubation at room 
temperature for 2 h, plates were washed three times. In each well, the captured 
immune complexes were further incubated with 100 µl streptavidin-HRP conjugate in 
Reagent Diluent for 1 h at room temperature away from direct light. Plates were 
subsequently washed 5 times. Substrate solution was prepared within 15 min prior to 
use by mixing equal volume of Substrate reagent A (hydrogen peroxide in a buffered 
solution) and Substrate B (3,3’,5,5’ tetramethylbenzidine in an organic solvent) from 
BD OptEIA™ Reagent Set B (BD Biosciences). Each well was added 100 µl 
substrate solution and incubated in dark for 30 min. The colormetrical reaction was 
stopped by adding 50 µl Stopping Solution (1M phosphoric acid) to each well. The 
optical density was determined immediately using a microplate reader (TECAN) at 
450 nm with the wavelength correction at 570 nm. The linearized standard curve was 
constructed by plotting the log of the cytokine concentrations versus the log of the OD. 
The concentration of each sample was read from the standard curve and then 
multiplied by the dilution factor.  
 
2.2.2.6 Caspase-1 activity assay 
moDCs (1×106) were either untreated or stimulated for 24 h with 500 ng/ml LPS, 100  
µg/ml imIgG or both. Each treatment was performed in duplicate. Cells were 
harvested by gentle scraping and washed once with ice-cold PBS (pH 8.0). Cells were 
lysed in 50 µl hypotonic lysis buffer (Appendix) by 4 cycles of freezing and thawing. 
The lysates were cleared by centrifugation at 12,000 rpm for 20 min at 4 °C. 
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Caspase-1 activity in these cell extracts was measured using the flurometric 
CaspACETM Assay System (Promega Co.). 96-well plate assay was performed 
according to the manufacturer’s instruction. Each cell extract sample was tested with 
three reaction mixtures. Components of a 100 µl caspase-1 activity assay reaction 
mixture were listed in Table 2.7. With the reaction mixtures, the plate was sealed with 
Parafilm and incubated at 37°C for 30 min. 2 µl of 2.5 mM caspase-1 substrate was 
subsequently added and incubated at 37°C for another 1 h in dark. The fluorescence 
was measured at 360 nm excitation wavelength and 460 nm emission wavelength 
within 2 h from the addition of substrate. The difference in the fluorescence unit 
between assay well and negative control well using the same cell extract reflected the 
contribution of caspase-1 activity. Results were calculated as relative fluorescence 
units (∆FU).  
 
Table 2.7 Caspase-1 activity assay reaction mixture 
Component Blank Assay Negative control
Caspase Assay Buffer 32 µl 32 µl 32 µl
DMSO 2 µl 2 µl -
DTT, 100mM 10 µl 10 µl 10 µl
Cell extract - 10 µl 10 µl
2.5mM caspase-1 inhibitor - - 2 µl
Deionized water to final volume 98 µl 98 µl 98 µl
∆FU= (mean assay FU) - (mean negative control FU) 
 
2.2.2.7 Lactate dehydrogenase (LDH) assay 
LDH, a stable cytosolic enzyme that is released upon cell lysis, was quantitatively 
measured using the Cyto Tox 96® Non-Radioactive Cytotoxicity Assay Kit from 
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Promega Co. moDCs (1×105) in 100 µl culture medium were unstimulated or 
activated in triplicate. 3 wells, containing only culture medium without cells, were 
used for the correction for background contributed by phenol red and endogenous 
LDH activity in the serum. Another 3 wells with unstimulated moDCs were required 
for the measurement of maximum LDH release. After 24 h, culture media from 
experimental wells and background control wells were collected and cleared by 
centrifugation at 12,000 rpm for 2 min. 10 µl of lysis buffer (10×) was added to the 
wells for maximum LDH release measurement, followed by 45 min incubation in cell 
incubator for cell lysis. Cell lysates were cleared by centrifugation. 50 µl of cell-free 
culture medium or cell lysates were then incubated with 50 µl of Substrate Mix in a 
96-well plate for 30 min at room temperature in dark. Reaction was stopped by 
addition of 50 µl Stop Solution to each well. The optical density at 490 nm was read 
immediately using a microplate reader (TECAN). Background reading was subtracted 
and cell death was calculated as: 
% cell death = sample LDH release (OD490) / maximum LDH release (OD490) 
 
2.3 Protein chemistry 
2.3.1 Protein concentration determination 
Protein concentration were determined using the Bio-Rad protein assay kit (Bio-Rad) 
developed based on the method of Bradford (Bradford, 1976). Assays were performed 
following the manufacturer’s standard protocol. Briefly, 8 serial dilutions of a 
standard BSA solution were prepared. The linear range of this assay is 0.05 mg/ml to 
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approximately 0.5 mg/ml. 10 µl of each dilution of BSA and the protein samples to be 
measured were added into microtiter plate wells. 200 µl of diluted dye reagent (1 part 
Dye Reagent Concentrate with 4 parts distilled water, filtered through 0.45µm filter to 
remove particulates) was added to each well, mixed thoroughly using a multi-channel 
pipet, and then incubated at room temperature for at least 5 min but no more than 1 h. 
Optical density was measured at 595 nm. The standard curve was constructed by 
plotting the standard concentrations versus OD595. Protein concentration was read 
from the standard curve.   
 
2.3.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Cells were lysed on ice in a lysis buffer (Appendix). After removing insoluble 
materials by centrifugation, protein concentration of the lysates was determined using 
the BCA reagent (Bio-Rad). 50 µg of each protein sample was mixed with 1/5 volume 
of 5× SDS-PAGE sample loading buffer (Appendix). The samples were boiled at 95 
°C for 10 min before loading onto the 12.5% gels. The gels were run, as described by 
Laemmli (Laemmli, 1970), in 1×SDS/Glycine buffer (25 mM Tris, 250 mM Glycine, 
0.1% SDS, pH 8.3) at 120 V until the dye front is approximately 1 cm from the 
bottom.  
 
2.3.3 Western blotting 
The separated proteins on the SDS-polyacrylamide gel were electro-blotted onto 
nitrocellulose membrane (Bio-Rad) in transfer buffer (Appendix) using an 
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electroblotting apparatus set (Bio-Rad) at 100 V and 250 mA for 1.5 h. After electro 
transfer, blots were blocked for 1 h in 5% non-fat milk dissolved in the TBST buffer 
(50 mM Tris (pH 7.5), 150 mM NaCl, 0.1% (v/v) Tween-20). The blots were 
incubated with 1 µg/ml primary antibody in 5% non-fat milk in TBST overnight at 
4ºC on a horizontal shaker. The next day, the blots were washed three times with 
TBST and incubated for 2 h with alkaline phosphatase-conjugated goat anti-mouse 
IgG (Bio-Rad) at the dilution of 1:2000 in 5% non-fat milk in TBST. After washing 
three times in TBST, blots were developed using the Immun-StarTM Stubstrate Pack 
(Bio-Rad). Luminescent signals were captured on CL-XposureTM Film (Pierce). 
 
2.4 Statistic analysis 
Statistic analysis was performed using the software SPSS for Windows, standard 
version (SPSS, Inc.). Independent-sample T test without equal variances assumed was 
used to compare means.  
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CHAPTER 3 RESULTS 
3.1 moDCs acquire distinct phenotypic properties after differentiation from 
monocytes 
As described in the aim of the study in chapter 1, the essential cell type investigated in 
this project is human DCs. Two main protocols have been widely used to generate 
human DCs in vitro from either peripheral blood monocytes (Sallusto and 
Lanzavecchia, 1994) or CD34+ precursors from cord blood (Caux et al., 1996). We 
used moDCs in this study. 2-3×108 PBMCs were isolated from 30-40 ml buffy coat by 
Ficoll-Paque gradient centrifugation. 2-4×107 monocytes were obtained from tissue 
culture plastic–adherent PBMCs after 2 h adhesion. 1.5-3×107 immature moDCs were 
generated over 6 days from monocytes in the presence of 20 ng/ml GM-CSF and 20 
ng/ml IL-4 in complete RPMI. Fresh medium and cytokines were replenished every 2 
days. Phenotypic changes after in vitro differentiation were evaluated by flow staining 
(Fig. 3.1A). As previously reported (Cao et al., 2006), monocytes expressed high 
surface CD14 but lacked surface CD1a. In contrast, moDCs expressed diminished 
surface CD14 but acquired heterogeneous but high surface CD1a.  
 
moDCs acquire antigen presenting capacities upon pathogen recognition. Phenotypic 
analysis of mature moDCs by flow cytometry was performed 48 h after LPS treatment 
(Fig. 3.1B). LPS stimulation initiated the process of DC maturation, during which 
surface expression of MHCII, costimulatory molecules such as CD80 and CD40 as 





Figure 3.1 Phenotypic properties of monocytes and moDCs (A) Monocytes 
isolated from PBMCs were cultured for 6 days with 20 ng/nl GM-CSF and 20 ng/ml 
IL-4 to yield immature moDCs. Freshly isolated monocytes and immature moDCs 
were surface-stained with the indicated monoclonal antibodies. Filled profiles are 
signals obtained with isotype IgG and open profiles are signals detected with specific 
antibodies. (B) moDCs were matured by stimulation with 500 ng/ml LPS for 2 days. 
Immature and mature moDCs were stained with the indicated antibodies. Filled 
profiles are signals obtained with isotype IgG. Dotted profiles represent immature 
moDCs and open profiles represent mature moDCs. Cells were analyzed by flow 
cytometry on FACSCalibur using the CellQuest software.  
 
These data showed that moDCs with typical DC phenotypes were cultured with the 





3.2 TLR activation elicits IL-1β secretion by monocytes but not moDCs 
Monocytes and DCs are at the first line of host defence. Upon encounter of pathogens, 
they secrete an array of cytokines. These cytokines have immunomodulatory roles in 
the onset and regulation of inflammation and in the activation and differentiation of T 
cells (Henderson et al., 1996; Luster, 2002). IL-1β is one of the major 
pro-inflammatory cytokines. LPS-activated monocytes have been reported to be the 
main IL-1β producer (Dinarello, 1991). However, less has been known about IL-1β 
production by DCs. Therefore, in this study, moDCs and monocytes, two closely 
related cell types, were compared in IL-1β production upon LPS stimulation (Fig. 
3.2A). Without stimulation, neither cell type produced IL-1β. 24 h LPS stimulation 
induced little IL-1β secretion from moDCs, but 20 times more IL-1β from monocytes 
(p≤ 0.002).  
 
This raised the question whether in general, moDCs produced less pro-inflammatory 
cytokines than monocytes upon LPS stimulation. To address this question, the 
secretion of TNF-α, another important pro-inflammatory cytokine, was compared as 
well (Fig. 3.2B). Results showed that LPS stimulation induced comparable TNF-α 
secretion from moDCs and monoctyes. Therefore, the stringent control is unique for 
IL-1β in moDCs.  
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Figure 3.2 IL-1β and TNF-α secretion from LPS-stimulated moDCs and 
monocytes Immature moDCs and monocytes (105 per well) were stimulated for 24h 
with 500 ng/ml LPS or unstimulated (con). Cell-free supernatants were assayed for 
IL-1β (A) and TNF-α (B) by ELISA. Results are the average of triplicate wells ± SD. 
One representative experiment of three independent experiments with similar results 
is shown. * Significant difference (p ≤ 0.002) was observed between moDC and 




We then asked whether the observed difference in IL-1β secretion between these two 
cell types was the specific property of LPS. Therefore, another two TLR ligands, PGN 
and flagellin, were also used to stimulate these cells (Fig. 3.3). Similar to LPS, PGN 
and flagellin triggered 6-7 times more IL-1β secretion from monocytes than from 
moDCs. This indicates that monocytes, which secret IL-1β upon stimulation through 






Figure 3.3 IL-1β secretion from moDCs and monocytes upon TLRs activation 
Immature moDCs and monocytes (105 per well) were stimulated for 24 h with 500 
ng/ml LPS, 10 µg/ml PGN, 2 µg/ml fagellin respectively or unstimulated (con). 
Cell-free supernatants were assayed for IL-1β by ELISA.  Results are the average of 
triplicate wells ± SD. One representative experiment of three independent 
experiments with similar results is shown. * Significant difference (p ≤ 0.002) was 
observed between moDC and monocyte in response to the same stimulus. 
 
3.3 IL-4 confers on moDCs stringent control over IL-1β secretion 
GM-CSF and IL-4 are two cytokines used to drive the cell differentiation from 
monocytes to moDCs. It has been reported that IL-4 could suppress LPS-induced IL-1 
production by human monocytes in a time- and dose-dependent manner (Donnelly et 
al., 1990). Therefore, the lack of IL-1β secretion might not be a property of DCs, but 
the consequence of the inhibitory effect of IL-4 or GM-CSF irrespective of monocytes 
or DCs.  To examine this, monocytes were stimulated for 24 h with LPS in the 
presence of GM-CSF, IL-4 or both. IL-1β in cell supernatants was measured by 
ELISA (Fig. 3.4). Results clearly showed that short-term exposure to GM-CSF or 




Figure 3.4 Effect of IL-4 and GM-CSF on IL-1β secretion from LPS-stimulated 
monocytes Freshly isolated blood monocytes were stimulated for 24h with LPS in the 
presence of 20 ng/ml GM-CSF or 20 ng/ml IL-4 or neither (con).  IL-1β in the 
supernatant was measure by ELISA. Results are the average of triplicate wells ± SD. 
One representative experiment of three independent experiments with similar results 
is shown. 
 
Long-term effect of these cytokines on IL-1β secretion was assessed as well. 
Monocytes were cultured for 6 days with GM-CSF but not IL-4 to generate 
macrophages. On day 7, macrophages and moDCs generated from monocytes of the 
same donor were stimulated with LPS for 24 h. IL-1β secretion was measured and 
compared (Fig. 3.5). Unlike moDCs, macrophages remained as potent as monocytes 
in IL-1β secretion upon LPS stimulation. We also attempted to culture monocytes 
with IL-4 alone for 6 days. However, it resulted in cell death. Therefore we were 
unable to assess how monocyte differentiation under IL-4 might affect IL-1β 
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secretion. Nonetheless, these results suggest that IL-4 might be essential in the 
differentiation process to deprive DCs of the ability to secrete IL-1β in response to 




Figure 3.5 IL-1β secretion from LPS-stimulated moDCs and macrophages 
Macrophages were generated from monocytes with 20 ng/ml GM-CSF in complete 
RPMI for 6 days. On day 7, Macrophages and immature moDCs were cultured 24 h in 
the absence (con) or presence of 500 ng/ml LPS. Cell-free supernatants were assayed 
for IL-1β by ELISA. Results are the average of triplicate wells ± SD. One 
representative experiment of three independent experiments with similar results is 
shown.*Difference (p=0.08) was observed between moDC and macrophage in 
response to LPS. 
 
 
3.4 LPS induces IL-1β synthesis, processing but not secretion in moDCs 
IL-1β production by monocytes and macrophages can be regulated at the levels of 
biosynthesis and secretion (Dinarello, 1996). It has been also reported that pro-IL-1β 
synthesis and its processing and secretion can be separately regulated in moDCs 
(Gardella et al., 2000). While CD4+ T cells drive the synthesis of pro-IL-1β without 
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processing, CD8+ T cells are responsible for the generation and secretion of mature 
IL-1β from pro-IL-1β producing moDCs. Therefore, it is possible that under 
inflammation conditions, LPS induces pro-IL-1β synthesis but not its processing and 
secretion by moDCs. To assess this possibility, intracellular IL-1β in LPS-stimulated 
moDCs was examined by western blotting (Fig. 3.6). In unstimulated moDCs, there 
was no IL-1β protein detectable. In LPS-stimulated moDCs, multiple forms of IL-1β 
were detected: the 31-kD unprocessed pro-IL-1β, the 28-kD intermediate products 
generated by the cleavage at Asp28 and the 17-kD mature IL-1β generated by the 
cleavage at Asp116 . Hence, LPS induces pro-IL-1β synthesis and processing in 




Figure 3.6 IL-1β synthesis and processing by LPS-stimulated moDCs Immature 
moDCs (2×106) were unstimulated or treated for 24 h with 500 ng/ml LPS. Cells were 
harvested on ice, washed once with cold PBS and lyzed with lysis buffer. Cell lysates 
were separated on two 12.5% SDS-PAGE gels and analyzed by western blotting 
probed with anti-IL-1β and anti-β-actin antibodies respectively. One representative 




3.5 LPS/ imIgG co-stimulation induces IL-1β secretion from moDCs 
As we showed above, TLR activation alone is not sufficient for IL-1β secretion from 
moDCs. We wondered whether whole bacteria, which would engage multiple surface 
PRRs and phagocytic receptors, were able to induce IL-1β secretion from moDCs. 
This would represent the typical pathogen-immune cell interactions. DH5α E. coli 
was used to stimulate moDCs. As shown in Fig. 3.7, DH5α-activated moDCs were 
capable of releasing as much IL-1β as that secreted by LPS-stimulated monocytes 
shown in Fig. 3.2A.  It implied that other PRRs or phagocytic receptors provide 




Figure 3.7 IL-1β secretion from DH5α-stimulated moDCs Immature moDCs (105 
per well) were stimulated for 24 h with bacteria DH5α at a bacteria to cell ratio of 
10:1 or unstimulated (con). Cell-free supernatants were assayed for IL-1β by ELISA.  
Results are the average of triplicate wells ± SD. One representative experiment of 
three independent experiments with similar results is shown. 
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Several lines of evidence brought our attention to FcγRs as the potential receptors to 
interplay with TLRs for IL-1β release. First, the dysregulation of IL-1β is involved in 
the development of autoimmune diseases (Abramson and Amin, 2002). Although 
TLRs and IL-1R mediate similar cellular signalling (Bowie and O'Neill, 2000; Sims, 
2002), IL-1R-/- but not TLR-/- mice were resistant to autoimmune disease (Su et al., 
2005). IL-1 is required for efficient DC activation, which in turn induces autoreactive 
CD4+ T cells and autoimmunity  (Eriksson et al., 2003). Therefore, a rigid control 
over DC secretion of IL-1β would help reduce autocrine DC activation by IL-1β so as 
to reduce IL-1β contribution to autoimmunity. This rigid regulation could be breached 
under autoimmune settings. IC deposition is described as a feature of many 
autoimmune diseases (Jancar and Sanchez Crespo, 2005; Tan Sardjono et al., 2003). It 
activates FcγRs and causes chronic inflammation and tissue damage. It has been 
shown in the mouse model of immune-complex-mediated arthritis (ICA) that elevated 
and prolonged expression of IL-1 was correlated to the higher FcγR expression level 
on the synovial lining and peritoneal macrophages (Blom et al., 2000). Therefore, 
FcγR might be involved in IL-1β regulation. Second, FcγR has been reported to 
modulate TLR signalling for tailored immune response (Underhill and Gantner, 2004). 
FcγR ligation on macrophages caused reduced IL-12 prduction and increased IL-10 
production in response to LPS (Sutterwala et al., 1997; Sutterwala et al., 1998). Thus, 
it is interesting to find out whether FcγR crosslinking can regulate TLR-induced 
IL-1β production.  
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We therefore examined whether immobilized IgG (imIgG), mimicking 
tissue-deposited ICs, could trigger IL-1β secretion. Human IgG (hIgG) was 
immobilized on the surface of 96-well plate at the concentration of 100 µg/ml to 
crosslink FcγRs. moDCs were cultured on this surface with or without LPS 
co-stimulation. As Fig. 3.8 demonstrated, like LPS, imIgG alone did not stimulate 
IL-1β secretion from moDCs. However, when moDCs were stimulated with LPS in 
hIgG-coated plates (LPS/imIgG), IL-1β was secreted. And the higher concentration of 
hIgG was used for well coating, the more IL-1β secretion was detected. Thus, imIgG 
co-stimulated IL-1β secretion was dose-dependent on imIgG, approaching maximum 





Figure 3.8 IL-1β secretion from LPS/ imIgG-co-stimulated moDCs (A) Immature 
moDCs were unstimulated (con) or activated for 24 h with 500 ng/ml LPS or 100 
µg/ml imIgG or both. (B) Immature moDCs were cultured for 24 h in the wells coated 
with increasing concentrations of hIgG up to 200 µg/ml and stimulated with (open bar) 
or without (black bar) 500 ng/ml LPS. Cell-free supernatants were examined for 
IL-1β production by ELISA. Results are the average of triplicate wells ± SD. One 
representative experiment of three independent experiments with similar results is 
shown. * Significant difference (p=0.001) was observed between LPS single 
stimulation and LPS/imIgG co-stimulation. 
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In comparison, monocytes were also co-stimulated with LPS and imIgG (Fig. 3.9). 
Similar to moDCs, imIgG enhaced LPS-induced IL-1β secretion from monocytes as 
well. This demonstrates that imIgG synergizes with LPS to induce IL-1β secretion 
from mononuclear phagocytes.  
 
 
Figure 3.9 IL-1β secretion from LPS/ imIgG-co-stimulated monocytes Monocytes 
were unstimulated (con) or activated for 24 h with 500 ng/ml LPS or 100 µg/ml 
imIgG or both. Cell-free supernatants were examined for IL-1β production by ELISA. 
Results are the average of triplicate wells ± SD. One representative experiment of 
three independent experiments with similar results is shown.  
 
 
In addition, the interplay between TLR and FcγR signalling in IL-1β production by 
moDC was not restricted to TLR4, because TLR2 or TLR5 also displayed the similar 





Figure 3.10 IL-1β secretion from moDCs with imIgG and TLR ligand 
co-stimulation Immature moDC were cultured with the indicated TLR ligands, i.e. 
LPS, PGN and flagellin in the absence (black bar) or presence (open bar) of 100 
µg/ml imIgG. After 24 h cell culture, supernatants were assayed for IL-1β by ELISA. 
Results are the average of triplicate wells ± SD. One representative experiment of 
three independent experiments with similar results is shown.  
 
3.6 ImIgG enhances LPS-induced IL-1β transcription, translation but 
down-regulates caspase-1 activity in moDCs 
The overall IL-1β production and activity has been reported to be tightly controlled at 
the following levels: transcription, translation and post-translational cleavage 
(Dinarello, 1996). Therefore, we investigated the underlying mechanism by which 
imIgG co-stimulates IL-1β secetion from moDCs at these regulatory levels.  
 
Firstly, IL-1β mRNA expression was measured by real-time PCR. moDCs from the 
same donor were divided into four treatment groups: unstimulated control group, LPS 
or imIgG single stimulation groups and LPS/imIgG co-stimulation group. Cells were 
harvested on ice after 6 hour treatment for total RNA extraction with Trizol. cDNA 
was reverse transcribed and used as template for real-time PCR to quantify IL-1β 
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transcript abundance. Relative quantification with external standards was applied. 
β-actin was used as the endogenous reference control for normalization of cDNA 
loading between samples. Serial dilutions of standard sample were performed to 
generate standard curves used for quantification of the target IL-1β and the reference 
β-actin in each experimental sample. For each sample, the level of target IL-1β 
mRNA was normalized to the reference β-actin mRNA level. The normalized IL-1β 
mRNA level in LPS-stimulated moDCs was set as 1,000 and used as a calibrator. The 
relative IL-1β mRNA levels for the rest of the samples were listed in Table 3.1. 
 
 
 Relative Expression Level ±SD 
Con 1.04 0.71 
LPS 1000  
imIgG 33.03 2.64 
LPS+imIgG 4946.52 490.15 
 
able 3.1 Effect of LPS and imIgG stimulation on IL-1β gene transcription 
ature moDCs (2×106) were cultured with the indicated stimuli for 6 h. Cells were 
T
Imm
harvested on ice, pelleted down by centrifugation and lysed in 1 ml Trizol for RNA 
isolation. Reverse transcription was performed immediately after RNA extraction. 
Transcribed cDNAs were used as templates for real-time PCR with specific primers 
for IL-1β (target gene) and β-actin (reference gene). The amplification specificity was 
validated by melting curve. The obtained crosspoints were used for the calculation of 
relative expression level. Results are the average of four independent experiments 
using cells cultured from different donors. The internal consistency between two 
independent runs using same cDNA template was verified.  
 
 87
As data implied, compared to unstimulated moDCs, moDCs that were stimulated in 
econdly, intracellular IL-1β protein synthesis and post-translational cleavage were 
hIgG-coated wells gained approximately 30 times increase in IL-1β mRNA 
expression, whereas cells stimulated with LPS obtained over 1000 times increase. In 
addition, FcγR engagement could further up-regulate LPS-induced IL-1β gene 
expression by 5 folds, which was 5000 times more than the basal level in 
unstimulated moDCs. The combined effect is synergetic rather than additive. It is 
possible that IL-1β gene transcription process is regulated at two rate-limiting steps. 
The primary rate-limiting step is the floodgate, under the control of LPS. The 
secondary rate-limiting step is induced by imIgG. Genes involved in the latter step 




evaluated by western blotting. Noteworthy, due to the lack of a secretory signal 
sequence, IL-1β is not released via the classic secretory pathway (Rubartelli et al., 
1990), which makes it impossible to study the cumulative total protein synthesis by 
disrupting the structure and function of the Golgi apparatus with Brefeldin A. Thus, 
signals obtained on the blot reflected the instant balance between new protein 
synthesis and mature cytokine secretion. As Fig. 3.11 showed, IL-1β was not 
detectable in unstimulated moDCs. In cells cultured in hIgG-coated wells, the 31-kD 
pro-IL-1β and the 28-kD intermediate form but not the 17-kD mature form was 
detected. In contrast, in LPS-stimulated moDCs, in addition to the abundant 31-kD 
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pro-IL-1β and the 28-kD intermediate form, a small fraction of 17-kD mature form 
was also detected. When moDCs were co-stimulated with imIgG and LPS, there was 
a slight increase in the intracellular pool of the 28-kD intermediate form and the 
17-kD mature IL-1β. Together with the ELISA data shown in Fig. 3.8A, which 
detected extracellur IL-1β, the difference in the levels of intracellular mature IL-1β 
pools in the differently treated moDCs suggested that imIgG co-stimulation enhances 






igure 3.11 IL-1β synthesis and processing by activated moDCs Immature moDCs 
×106) were unstimulated or treated for 24 h with 500 ng/ml LPS, 100 µg/ml imIgG 
tly, the activity of caspase-1, which cleaves pro-IL-1β to generate mature IL-1β, 
or both. Cells were harvested on ice, washed once with cold PBS and lyzed with lysis 
buffer. Cell lysates were separated on two 12.5% SDS-PAGE gels and analyzed by 
western blotting with anti-IL-1β and anti-β-actin respectively. Recombinant human 
IL-1β (rhIL-1β) was loaded as reference marker. One representative experiment of 
three independent experiments with similar results is shown. 
  
Las
was assessed with a commercial fluorometric kit from Promega. moDCs were seeded 
at 2×106 per well in a 6-well plate. Different stimulations as indicated were conducted 
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in duplicate. After 6 h incubation, cells were harvested on ice and lysed in hypotonic 
lysis buffer. The caspase-1 activity in the lysate was measured (Fig. 3.12).  
 
 
Figure 3.12 Caspase-1 activity in activated moDCs Immature moDCs (2×106) were 
unstimulated (con) or stimulated for 6 h with 500 ng/ml LPS, 100 µg/ml imIgG or 
esults demonstrated that immature moDCs expressed functional caspase-1. LPS 
both. Cells were harvested on ice, washed once with cold PBS and lyzed in hypotonic 
lysis buffer by repeated freeze and thaw. Cell lysates were assayed for caspase-1 
activity by the Fluorometric CaspACE Assay System. Results are the average of 
duplicate wells ± SD. One representative experiment of three independent 
experiments with similar results is shown. *Significant difference (p≤ 0.001) was 
observed in cells with indicated treatments versus the unstimulated cells.  
 
R
stimulation did not affect caspase-1 activity. In contrast, FcγR crosslinking 
dramatically suppressed caspase-1 activity, even in the presence of LPS. These data 
indicate that: (i) the low level of IL-1β induced by LPS is not due to defective 
processing of pro-IL-1β by caspase-1; (ii) the synergistic effect of imIgG on 
LPS-induced IL-1β release is not due to an increase in intracellular caspase-1 activity; 
and (iii) alternative IL-1β cleavage mechanism may be trigged upon FcγR 
engagement. The observation of the release of bioactive IL-1β via mechanisms other 
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than caspase-1 activation has been previously reported (Gardella et al., 2000). The 
secretion of bioactive IL-1β by moDCs was induced by interaction with alloreactive T 
cells. And no significant decrease in IL-1β bioactivity was detected in the 
supernatants of the mixed cell culture when caspase-1 inhibitor was added upon cell 
stimulation. This shows that alloreactive T cells induce IL-1β secretion from moDCs 
in a manner which is independent of caspase-1 activity. 
 
Altogether, these lines of evidence imply that the production of bioactive IL-1β by 
.7 ImIgG stimulates IL-1β secretion from moDCs through FcγRII 
cγRII (CD32) 
moDCs is controlled by two separate signals: (i) one, represented by LPS, for 
pre-IL-1β synthesis and low level of processing; (ii) the other, provided by FcγR 
crosslinking, for optimal processing of pre-IL-1β and secretion of mature IL-1β. 
However, between processing and secretion, it remains a question which step is rate 
limiting and whether they are mutually interactive. 
 
3
imIgG may be recognized by three types of FcγRs, i.e. FcγRI (CD64), F
and FcγRIII (CD16). We examined the surface expression profiles of these receptors 
on moDCs by flow cytometry (Fig. 3.13). FcγRI and FcγRII but not FcγRIII were 
detected on moDCs. It has been reported that moDCs express mainly FcγRII (Banki et 
al., 2003). As for FcγRI expression, we excluded the possibility of non-specific false 
signal, because human embryonic kidney line 293T, which is negative for FcγRI 
expression was stained negative using the same antibody. We noticed that the clone of 
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FcγRI detection antibody we used was different from that used in previous report. 
Thus, it is possible that the higher sensitivity of our antibody allowed us to detect 
FcγRI expression on moDCs.  
 
              
                  
 
igure 3.13 FcγR expression profiles on moDCs by flow cytometry Immature 
oDCs (3×105) were surface-stained with the indicated monoclonal antibodies. 293T 
o determine which FcγR is involved in imIgG-elicited IL-1β secretion, moDCs were 
F
m
cells (3×105) were surface-staining with anti-CD64 as a negative control. Filled 
profiles are signals obtained with isotype IgG and open profile are signals detected 
with respective specific antibodies. 
 
T
pre-incubated for 1 h at 4 °C with 10 µg/ml specific blocking antibodies for each 
FcγR respectively, and then cultured in 100 µg/ml hIgG-coated wells in the presence 
of 500 ng/ml LPS for another 24 h. Secreted IL-1β in supernatant was measure by 
ELISA (Fig. 3.14). IL-1β secretion was not inhibited by antibodies specific for FcγRI 
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or FcγRIII. However, it was inhibited more than 50% (p<0.05) by FcγRII blocking 
antibody, compared to isotype control mouse IgG. In addition, cells were 
pre-incubated with combinations of two different FcγR-blocking antibodies. 
Simultaneous incubation of moDCs with FcγRI and FcγRIII antibodies showed no 
inhibition in LPS/imIgG-induced IL-1β secretion. Throughout the experiment, 
inhibition was only observed when FcγRII antibody was used. Additional FcγRI or 




Figure 3.14 Effect of specific FcγR blockade on IL-1β secretion from LPS/ 
imIgG-co-simulated moDCs Immature moDCs were pre-incubated with 10 µg/ml 
indicated blocking antibodies for 1 h on ice and then simulated with 500 ng/ml LPS in 
hIgG- coated wells for another 24 h.  Cell-free supernatants were measured for IL-1β 
by ELISA. Results are the average of triplicate wells ± SD. One representative 
experiment of three independent experiments with similar results is shown. 





3.8 Effect of signaling inhibitors on IL-1β secretion from moDCs 
tion via FcγRII. 
oDCs were pre-treated with inhibitors for 2 h before LPS and imIgG co-stimulation. 
imIgG co-stimulation with LPS was shown to induce IL-1β secre
However, the signaling mechanism leading to this secretion was not clear. 
Cross-linking of FcγRs activates tyrosine kinases of the Src family, which in turn 
recruits and activates Syk. Signaling downstream of Syk activation may diverge at 
several points (Ravetch and Bolland, 2001). In general, two main pathways can be 
identified: PI3-K-PLC-γ-Ca2+ pathway and Ras/Rac-MAPK pathway. Thus, inhibitors 
against signaling molecules in these pathways were used to identify potential 
regulatory molecules.  
 
m
As Fig. 3.15 showed, in the PI3-K-PLCγ-Ca2+pathway, inhibition of PI3-K by 
LY20094 increased IL-1β secretion by about 2 folds. Akt and mTor are two major 
signaling molecules immediately downstream of PI3-K. Akt inhibition resulted in 
40% reduction in IL-1β secretion whereas mTor inhibition did not lead to significant 
change. It is also known that PI3-K can activate PLCγ, which catalyzes PIP2 to 
generate DAG for PKC activation and IP3 for Ca2+ mobilization. Specific inhibitor 
against DAG-dependent PKCs had no effect on IL-1β secretion. The impact of Ca2+ 
mobilization on IL-1β regulation will be discussed in the next section. In 
Ras/Rac-MAPK pathway, Rac1 is important in FcγR-mediated phagocytosis (Aderem 
and Underhill, 1999). Inhibition of Rac1 by NSC23766 suppressed IL-1β secretion by 
95%. PD98059, JNK inhibitor II and SB203580 were used to suppress the activity of 
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MEK, JNK and p38 MAPKs respectively. These three classes of MAPKs displayed 
distinct function in the control of IL-1β secretion. JNK and MEK inhibition 
suppressed LPS/imIgG induced IL-1β secretion by 90% and 80% respectively, while 
p38 MAPK inhibition increased IL-1β secretion by more than 2.5 folds. Therefore, 
Rac1, JNK and MEK are key molecules in LPS/imIgG-induced IL-1β secretion. 





Figure 3.15 Effect of signaling inhibitors on IL-1β secretion from LPS/ 
imIgG-co-stimulated moDCs Immature moDCs were pre-incubated for 2 h with 
inhibitors against the signaling molecules listed or equivalent volume of solvent 
DMSO or untreated (con). Then cells were stimulated in 100 µg/ml hIgG-coated cells 
for another 24 h with 500 ng/ml LPS. Cell-free supernatants were measured for IL-1β 
by ELISA. Results are the average of triplicate wells ± SD. One representative 
experiment of three independent experiments with similar results is shown. 




The same panel of inhibitors was used to identify the molecules responsible for the 
stringent control over LPS-induced IL-1β release as well. moDCs were pre-treated 
with the inhibitors for 2 h before LPS stimulation. As Fig. 3.16 showed, in the 
PI3-K-PLCγ-Ca2+pathway, PI3-K inhibitor increased IL-1β secretion by more than 10 
folds. The inhibitors for Akt, mTor and PKC did not affect IL-1β secretion. In 
Ras/Rac-MAPK pathway, Rac1 inhibition had no significant effect on IL-1β secretion. 
The inhibitors for MEK and JNK inhibited IL-1β secretion by 45% and 65% 
respectively while the inhibitor for p38 MAPK increased IL-1β secretion by 3 folds. 
As a conclusion, PI3-K and p38 MAPK are major negative controller of IL-1β 




Figure 3.16 Effect of signaling inhibitors on IL-1β secretion from LPS-stimulated 
moDCs Immature moDCs were pre-incubated for 2 h with the inhibitors against the 
signaling molecules listed or equivalent volume of solvent DMSO or untreated (con). 
Then cells were stimulated for another 24 h with 500 ng/ml LPS. Cell-free 
supernatants were measured for IL-1β by ELISA. Results are the average of triplicate 
wells ± SD. One representative experiment of three independent experiments with 
similar results is shown. Significant differences, *p≤0.05 and **p≤0.01, were 
observed versus cells with solvent DMSO. 
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3.9 LPS/imIgG-induced IL-1β secretion from moDCs involves Ca2+ influx 
The essential role of Ca2+ in the regulation of IL-1β secretion has been studied by 
different research groups but the underlining mechanism remains controversial to date. 
Gudipaty demonstrated in monocytes, macrophages, and HEK-239 cells that a rapid 
secretion of mature IL-1β upon P2X7R activation depended on the influx of 
extracellular Ca2+ and a sustained rise in cytosolic Ca2+ (Gudipaty et al., 2003). 
Conversely, Brough claimed that the absence of Ca2+ in culture medium did not affect 
the release of processed IL-1β, whereas the increase in intracellular Ca2+ 
concentration was important for ATP-induced IL-1β processing and release (Brough 
et al., 2003). In order to clarify this issue, we examined the role of Ca2+ in 
LPS/imIgG-induced IL-1β secretion from moDCs.  
 
Intracellular Ca2+ mobilization from ER store is an event secondary to PLCγ 
activation upon FcγR crosslinking (Lin et al., 1994). Ionomycin, a calcium ionophore, 
triggers the release of intracellular Ca2+ store as well. And it has been reported that 
Ca2+ ionophores increase IL-1 production in human monocytes (Matsushima and 
Oppenheim, 1985).  To assess the role of intracellular Ca2+ mobilization in IL-1β 
secretion from moDCs, cells were stimulated with LPS in the absence or presence of 
ionomycin at 500 ng/ml (0.67 µM) for 24 h. IL-1β in the medium was measured by 
ELISA (Fig. 3.17). Results demonstrated that ionomycin induced significant increase 
in IL-1β release from LPS-activated moDCs. This implies that an increase in 




Figure 3.17 Ionomycin triggers IL-1β secretion from LPS-stimulated moDCs. 
Immature moDCs is unstimulated (control), or stimulated with 500 ng/ml LPS. 500 
ng/ml ionomycin or equivalent volume of ethanol solvent or culture medium was 
added together with LPS for stimulation. After 24 h incubation, cell-free supernatants 
were measured for IL-1β by ELISA. Results are the average of triplicate wells ± SD. 
One representative experiment of three independent experiments with similar results 
is shown. *Significant differences (p<0.05) were observed.  
 
Next, to determine whether Ca2+ entry across the plasma membrane is important for 
IL-1β release, EGTA, a membrane non-permeable Ca2+ chelator, was used to 
neutralize the extracellular Ca2+ in the culture medium. One molecules of EGTA can 
chelate two molecules of Ca2+. Plain RPMI-1640 contains about 0.44 mM Ca2+.  
Thus, moDCs were bathed in normal medium or media containing increasing 
concentrations of EGTA from 0.4 to 5 mM. moDCs were co-stimulated with LPS and 
imIgG. High concentrations of EGTA may dramatically alter intracellular Ca2+ 
homeostasis and result in cell necrosis or apoptosis. During cell necrosis, the 
membrane disintegration leads to non-specific leakage of intracellular molecules. In 
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order to rule out the possibility that the increased IL-1β release in supernatants is due 
to the increased cell lysis caused by EGTA, LDH release measurement was included. 
 
 
     
Figure 3.18 EGTA inhibits IL-1β secretion from LPS/ imIgG-co-stimulated 
moDCs. (A) Immature moDCs were stimulated with 500 ng/ml LPS in the presence 
of increasing concentrations of EGTA as indicated. After 24 h incubation, cell-free 
supernatants were measured for IL-1β by ELISA. (B) The release of lactate 
dehydrogenase (LDH) in (A) was measured using the CytoTox 96 Non-Radioactive 
Cytotoxicity Assay Kit. Results are the average of triplicate wells ± SD. One 
representative experiment of three independent experiments with similar results is 
shown. *Significant differences (p<0.05) were observed versus cells without EGTA.  
 
As Fig. 3.18A showed, at 0.4 mM, EGTA did not inhibit IL-1β secretion by 
LPS/imIgG-stimulated moDCs. However, at 2 and 5 mM, it completely attenuated 
IL-1β release from moDCs (p<0.05). There is no significant increase in LDH release 
from EGTA treated cells, indicating no increase in cell lysis caused by EGTA at these 
concentrations (Fig. 3.18B).  Therefore, imIgG co-stimulation with LPS might cause 
IL-1β secretion through enhanced Ca2+ influx and intracellular Ca2+ mobilization. 
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3.10 LPS/imIgG-induced IL-1β secretion from moDCs requires the activation of 
P2X7R 
An ATP-induced IL-1β secretion model has been intensively studied (Dinarello, 
2005). In this model, ATP activates surface ion-gated receptor P2X7 and initiates the 
efflux of K+ from the cell via a potassium channel. This leads to the influx of Ca2+, 
which in turn activates phosphatidylcholine-specific phospholipase C (PC-PLA2). 
PC-PLA2 facilitates lysosomal exocytosis and secrtion of IL-1β .  In addition, 
P2X7R has been reported to be expressed on human moDCs (Ferrari et al., 2000). 
Herein, we assessed the role of P2X7R in LPS/imIgG induced IL-1β secretion from 
moDCs.  
 
First, the expression profile of P2X7R was defined by RT-PCR on unstimulated 
immature moDCs and activated moDCs stimulated with LPS, imIgG or both (Fig. 
3.19).  As data showed, unstimulated immature moDC displayed little P2X7R 
mRNA expression. LPS stimulation did not increase its expression. However, FcγR 
crosslinking significantly up-regulated P2X7R mRNA level in moDCs. 
Co-stimulation with both stimuli did not exhibit additive or synergistic effect on 
P2X7R expression. This may suggest that FcγR crosslinking up-regulates P2X7R in 




Figure 3.19 P2X7R gene expression in activated moDCs Immature moDCs (2×106) 
were cultured with the indicated stimuli, 500 ng/ml LPS or 100 µg/ml imIgG for 6 h. 
RNA was isolated from each sample. Transcribed cDNA was used as template for 
PCR with specific primers for P2X7R and β-actin. The PCR products were separated 
on 1% (w/v) agarose gels and visulized using ethidium briomide.  
 
Second, P2X7R  antagonist oxidized ATP (oATP), a Schiff-base-forming reagent, has 
been used to compete with ATP for receptor binding and block the downstream 
activation signaling. It helps investigate the involvement of this receptor in 
FcγR-induced IL-1β secretion. Before use, the blocking efficiency of oATP was 
validated. It has been reported that ATP acts as an agonist to promote LPS-induced 
secretion of IL-1β (Griffiths et al., 1995; Perregaux et al., 2000) and pre-treatment 
with oATP inhibits this effect (Elssner et al., 2004).  Thus, moDCs were primed with 
500 ng/ml LPS overnight to induce pre-formed IL-1β, and then pre-treated with or 
without 250 µM oATP for another 2 h followed by 30 min exposure to 5 mM ATP. 
Cell-free supernatants were assayed for IL-1β by  ELISA (Fig. 3.20). Without oATP 
treatment, LPS-primed moDCs rapidly released IL-1β in response to brief ATP 
exposure. oATP itself did not induce IL-1β release from moDCs. Howerver, oATP 
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pre-treatment abolished the effect of ATP, and resulted in dramatic decrease in   




Figure 3.20 oATP inhibits ATP-promoted IL-1β secretion from LPS-stimulated 
moDCs Immature moDCs were primed with 500 ng/ml LPS overnight and then 
treated as indicated. 250 µM oATP was added 2 h before the exposure to 5 mM ATP. 
Cell-free supernatants were measured for IL-1β by ELISA. Results are the average of 
duplicate wells ± SD. One representative experiment of three independent 
experiments with similar results is shown. ** Significant differences (p≤0.002) was 
observed.  
 
Using oATP, the effective P2X7R antagonist, we then examined whether 
LPS/imIgG-elicited IL-1β release, which involves Ca2+ influx, was mediated through 
P2X7R activation. moDCs were co-stimulated with imIgG and LPS in the presence or 
absence of different dosages of oATP. After 24 h incubation, supernatants were 
measured for IL-1β by ELISA (Fig. 3.21). oATP at 0.25 mM inhibited 
LPS/imIgG-induced IL-1β secretion by approximately 50%, although it resulted in 
nearly complete inhibition of ATP-elicited IL-1β secretion (Fig. 3.20). Increase of 
oATP concentration to 0.5 mM and 1.0 mM showed no further inhibition. This 
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suggests that (i) P2X7R activation plays a partial role in LPS/imIgG-elicited IL-1β 
secretion; and (ii) other parallel mechanisms may exist that also regulate IL-1β 




Figure 3.21 oATP inhibits imIgG-promoted IL-1β secretion from 
LPS-stimulated moDCs. Immature moDCs cultured in 100 µg/ml hIgG-coated wells 
were co-stimulated for 24 h with 500 ng/ml LPS in the presence of increasing 
concentrations of oATP as indicated. Cell-free supernatants were measured for IL-1β 
by ELISA. Results are the average of duplicate wells ± SD. One representative 
experiment of three independent experiments with similar results is shown. 
**Significant differences (p≤0.002) were observed. 
 
Next, we accessed whether P2X7R ligands were release from moDCs upon FcγR 
crosslinking in our experimental setting. Immature moDCs were cultured overnight in 
uncoated or 100 µg/ml hIgG-coated wells. The next day, these conditioned culture 
media were harvested and cleared by centrifugation. They were then used to 
co-stimulate new wells of immature moDCs with 500 ng/ml LPS. After 24 h 
co-stimulation, IL-1β in supernatant was measured by ELISA (Fig. 3.22). Results 
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showed that the conditioned culture medium from imIgG-stimulated moDCs 
enhanced IL-1β secretion from LPS-activated moDCs by more than 2 folds. However, 
it failed to achieve the 10-fold increase in IL-1β secretion caused by direct FcγR 
crosslinking (Fig. 3.8A). There might be two possible explanations for this relatively 
low enhancement by the conditioned medium. First, P2X7R ligands are unstable. Two 
known P2X7R ligands are ATP (Ferrari et al., 1997; Surprenant et al., 1996) and the 
peptide LL37 (Elssner et al., 2004). ATP might be hydrolyzed by the enzyme in the 
culture medium whereas the peptide LL37 may also be degraded by extracellular 
proteinases. Second, in addition to P2X7R activation, other intracellular signaling 




Figure 3.22 Conditioned medium from imIgG-activated moDCs elicits IL-1β 
secretion from LPS-stimulated moDCs. Immature moDCs were cultured in 
uncoated or 100 µg/ml hIgG-coated wells overnight. Conditioned cell-free 
supernatants were collected, supplemented with 500 ng/ml LPS and used to culture 
new wells of immature moDCs. After 24 h stimulation, IL-1β in the media was 
assayed by ELISA. Results are the average of duplicate wells ± SD. One 
representative experiment of three independent experiments with similar results is 




This study revealed several novel aspects in the regulation of IL-1β production in 
moDCs: (i) TLR activation induces IL-1β synthesis but not secretion in moDCs; (ii) 
Co-stimulation of moDCs through TLR and FcγRII causes both synthesis and 
secretion of IL-1β; (iii) This synergistic effect involves P2X7R activation and Ca2+ 
influx and mobilization; (iv) PI3-K and p38 MAPK are negative regulators of IL-1β 
production in moDCs while JNK, MEK and Rac1 are essential for optimal 
LPS/imIgG-induced IL-1β release. Collectively, these results suggest a more rigid 
control of IL-1β production by DCs compared to monocytes and macrophages. The 
ability of imIgG to co-stimulate IL-1β secretion from moDCs implies a possible 
mechanism for the breach of IL-1β control under autoimmune conditions.  
 105
CHAPTER 4 DISCUSSION 
4.1 The regulation of IL-1β production differs between monocytes and moDCs 
In this study, we investigated IL-1β synthesis, processing and secretion in moDCs and 
the underlying regulation mechanisms. Our data revealed the difference in IL-1β 
production between monocytes and moDCs. For human peripheral monocytes, a 
single stimulation by bacterial products is sufficient to drive synthesis, processing and 
secretion of bioactive IL-1β. In contrast, moDCs require at least two signals to release 
mature IL-1β: one, represented by microbial structures, induces gene expression, 
protein synthesis and post-translational cleavage; the other, FcγR activation as we 
showed, triggers secretion of processed bioactive IL-1β.  
 
Our observation that moDCs secreted little mature IL-1β in response to LPS is partly 
in line with the early report (Gardella et al., 2000). However, by western blotting, 
Gardellar demonstrated that there was no trace of 17-kD mature IL-1β in cell lysates 
or supernatants from LPS-stimulated moDCs. And 10-, 20-kD subunits of activated 
caspase-1 were also undetectable. These implied that LPS was insufficient to trigger 
pro-IL-1β processing in moDCs. On the contrary, we were able to detect 17-kD 
mature IL-1β in cell lysates of LPS-activated moDCs by western blotting.  
Caspase-1 activity was also detectable through sensitive luminescent assay. The 
discrepancy between the early report and our data might be explained by the distinct 
stimulation condition and detection time points. In our study, after 6 day culture in the 
presence of GM-CSF and IL-4, moDCs were harvested and washed with PBS once 
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prior to any experimental stimulation. The washing step is to remove residual IL-4 in 
the culture medium, because IL-4 has been shown to inhibit IL-1β production in 
human monocytes by decreasing the steady-state levels of IL-1β (Donnelly et al., 
1990; Essner et al., 1989; Hart et al., 1989) and by suppressing caspase-1 activity 
(Kim et al., 2004). After washing, moDCs were resuspended in the fresh medium free 
of GM-CSF/IL-4 for further stimulation. In contrast, Gardellar group stimulated DCs 
for 40 h with LPS in the presence of GM-CSF/IL-4. Consequently, the presence of 
suppressive cytokine IL-4 may skew the response of DCs to microbial structures, 
leading to reduced caspase-1 activity and IL-1β maturation.  
 
The difference in IL-1β production upon TLR activation between monocytes and 
moDCs may reflect the distinct functions of these two cell types. Monocytes are the 
major mononuclear phagocytes monitoring the host immune system in the blood 
circulation (Abbass, 2005b). They are mainly involved in inflammation in innate 
immunity. IL-1β is one of the key mediators in host response to microbial invasion, 
inflammation and tissue injury. It acts on a large range of cells and organs and induces 
secondary cytokines, including, IL-6, CSF and chemokines (Dinarello, 1997). 
Therefore, an immediate but transient burst of IL-1β secretion by monocytes is 
necessary to initiate the acute inflammatory response. Compared to monocytes, DCs 
are more specialized and potent in antigen presentation and initiation of T 
cell-dependent primary immune response (Guermonprez et al., 2002). The activation 
and maturation status of DCs and the cytokine environment on the DC-T cell interface 
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determines the direction of T cell differentiation and the strength of T cell activation. 
As reviewed in the introduction chapter, IL-1β is essential for T cell priming, 
activation and subsequent T cell-dependent immune response. Therefore, the stringent 
regulation of IL-1β secretion by DCs is critical for the delicate control of adaptive 
immune development.  
 
The requirement for additional signals to induce IL-1β secretion from moDCs as 
compared to monocytes, indicates that different temporal and spatial intracellular 
transportation of IL-1β may occur in the two cell types. A route of IL-1β secretion, 
originally described by Bakouche et al.(1987), involves translocalization of IL-1β to 
secretory lysosomes followed by exocytosis. IL-1β was found in the cytosol of 
LPS-treated human monocytes as the precursor and in lysosomes as the bio-active 
form. This suggests that after synthesis and processing of cytosolic IL-1β precursor, 
the 17-kD bio-active IL-1β was translocated to lysosomal vesicles. IL-1β was also 
found co-localized with the endolysosomal hydrolase cathepsin D or the lysosomal 
marker Lamp-1, supporting the above-mentioned exocytosis model (Andrei et al., 
1999). In another study, IL-1β was detected to be co-localized with cathepsin D, 
Lamp-1, and caspase-1 by subcellular fractionation and immunoelectron microscopy 
(Wewers, 2004). The sequestering of caspase-1 to lysosomes for IL-1β processing 
provides a mechanism whereby pro-IL-1β is processed without the caspase-1 
inducing apoptosis. According to the above model, immunofluorescence may be used 
to track IL-1β trafficking in moDCs as compared with monocytes. The cells can be 
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cultured on cover slips, stimulated with LPS and fixed at different time points, 
followed by immunofluorescent detection of IL-1β, cathepsin D, Lamp-1 and 
caspase-1. A delay or defect in IL-1β co-localization with caspase-1 or Lamp-1 is 
possible. 
 
4.2 FcγRs regulates IL-1β production by moDCs 
FcγR engagement not only mediates antigen uptake via phagocytosis (Underhill and 
Ozinsky, 2002), but also induces inflammatory cytokines such as TNF-α, IL-6 and 
IL-1 (Tan Sardjono et al., 2003). However, our data showed that in moDCs, FcγR 
crosslinking by imIgG triggered far less IL-1β gene transcription and protein 
synthesis, compared to microbial stimuli. In addition, FcγR activation down-regulated 
the activity of caspase-1, the enzyme responsible for IL-1β maturation. As a result, 
there was hardly any IL-1β secreted into medium and any detectable 17-kD mature 
IL-1β in cell lysate.  
 
The distinct ability between TLR and FcγR to induce IL-1β gene expression in 
moDCs might be explained by the distinct downstream activated nuclear factors. The 
IL-1β promoter contains binding motifs for three transcription factors: (i) NF-IL6 
(C/EBPβ); (ii) NF-κB; and (iii) Spi-1 (PU.1). It has been reported in THP-1 cells, a 
monocyte/macrophage-like cell line, that NF-κB and C/EBPβ bound to the IL-1β 
promoter upon LPS stimulation (Basak et al., 2005). Therefore, the inability of FcγR 
to induce abundant IL-1β transcripts might be due to lower activation of these two 
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nuclear factors, compared to LPS stimulation. In order to verify this hypothesis, the 
NF-κB or the C/EBPβ-binding elements can be cloned into a vector carrying 
LUCIFERASE as the reporter gene.  These two reporter constructs can be transfected 
into THP-1 cells separately. Transfected THP-1 cells will then be stimulated with 
either LPS or imIgG. Sensitive luciferase activity assay can be performed to analyze 
the strength of gene transcription. 
 
In addition, we document for the first time that FcγR signaling regulates caspase-1 
activity. Our data showed that FcγR crosslinking suppressed caspase-1 activity and 
this inhibitory effect could not be neutralized by co-stimulation with LPS. Caspase-1 
is a pro-inflammatory caspase (Martinon and Tschopp, 2004). It cleaves the 
precursors of pro-inflammatory cytokines IL-1β and IL-18 to generate active mature 
forms. The only physiological stimulus reported in phagocytes for caspase-1 
activation is LPS (Chin and Kostura, 1993; Schumann et al., 1998). LPS induces 
moderate caspase-1 activation in THP-1 cell line. However, the signaling downstream 
of TLR4 activation, leading to caspase-1 activation, is not well defined. Janus kinase 
3 (JAK3) has been reported to down-regulate LPS-induced caspase-1 activation 
through enhancing IL-10 production (Kim et al., 2004). Ligation of FcγRs by 
IgG-opsonized Leishmania amastigotes induces synthesis and secretion of IL-10 
(Kane and Mosser, 2001). And mice lacking the common γ-chain of FcR have a 
reduced numbers of cells producing Th2-type cytokines, including IL-4 and IL-10 
upon Leishmania infection (Padigel and Farrell, 2005). Therefore, it is possible that 
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FcγR induces more IL-10 than LPS in moDCs, which in turn inhibits caspase-1 
activity. In order to examine this possibility, a series of experiments will be performed 
in the future study: (i) IL-10 production by moDCs will be measured upon LPS or 
imIgG activation. (ii) IL-10R mRNA level and surface expression in moDCs will be 
detected by RT-PCR and flow cytometry respectively. (iii) moDCs will be stimulated 
with imIgG in the presence of IL-10 neutralizing antibody or its isotype control 
antibody. Caspase-1 activity in these cells will be assayed and compared. (iv) 
Caspase-1 activity will also be measured in moDCs that are stimulated with 
recombinant human IL-10. (v) If IL-10 indeed down-regulates caspase-1 activation in 
moDCs, the pharmacological inhibitors will be used to identify key signaling 
molecules in IL-10 pathway that mediate the inhibition effect. Further more, we 
would like to extend the investigation of caspase-1 regulation to other 
anti-inflammatory cytokines such as TGF-β.  
 
Interestingly, we also found that while FcγR crosslinking down-regulated capase-1 
activity, it enhanced IL-1β secretion from LPS-activated moDCs. This implies that an 
alternative mechanism of IL-1β processing is triggered upon FcγR activation. MMPs, 
namely stomelysin-1 (MMP-3), gelatinases A (MMP-2) and B (MMP-9) have been 
described to generate biologically active IL-1β independent of caspase-1 (Schonbeck 
et al., 1998). Over-expression of IL-1β occurs in various inflammatory diseases, 
including RA and atherosclerosis (Dinarello, 1996). In these conditions, MMPs are 
also induced (Ahrens et al., 1996; Galis et al., 1994; Unemori et al., 1991). 
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Macrophages and vascular endothelial and smooth muscle cells over-express MMPs 
at the sites of inflammation (Galis et al., 1994; Henney et al., 1991; Zucker et al., 
1995). moDCs are also able to express and secrete MMPs (Kouwenhoven et al., 2002). 
Therefore, we hypothesize that FcγR crosslinking might induce MMPs for pro-IL-1β 
processing, in spite of reduced caspase-1 activity. To test this hypothesis in the future 
study, gene expression of MMPs in imIgG-stimulated moDCs will be determined by 
RT-PCR; protein synthesis will be detected by intracellular flow staining; and protein 
secretion will be measured by immunoprecipitaion and western blotting. Specific 
neutralizing antibodies will also be used to identify the role of each MMP in IL-1β 
processing in our experimental setting.  
 
In addition, in our study, a band between 17-kD and 28-kD was observed in the cell 
lysate of LPS and LPS/imIgG stimulated moDCs (Fig. 3.11). The identity and 
bioactivity of this form of IL-1β will be of great interest in the follow-up study. In 
general, the activity of the final cleaved IL-1β product diminishes rapidly when the 
cleavage site moves away from the authentic Asp116 site, cleaved by caspase-1. Mast 
cell chymase and chymotrypsin generate molecules, which are two and three residues 
longer than capspase-1 generated mature IL-1β, with no change in activity (Mizutani 
et al., 1991). Trypsin and elastase, in contrast, generate polypeptides that are 13 and 
41 amino residues longer than caspase-1 generated mature IL-1β, but result in almost 
complete loss of activity (Black et al., 1988). Therefore, it is possible that the addition 
form of IL-1β observed in our study has little bioactivity. To test this possibility, a 
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sensitive in situ IL-1β bioactivity assay has to be established after the proteins in the 
lysate have been separated by the native gel and transferred to the blot. Currently 
available biological tests used for IL-1β, such as the thymocyte costimulator (LAF) 
assay, only applies for the detection of bioactive IL-1 concentration in biological 
fluid. 
 
Furthermore, using specific blocking antibodies, we identify FcγRII (CD32) as the 
major FcγR involved in imIgG-induced IL-1β secretion. We showed that blockade of 
CD32, rather than CD64 (FcγRI) or CD16 (FcγRIII), led to a significant reduction of 
IL-1β secretion from moDCs upon LPS/ imIgG costimulation. CD32 is composed of 
two isoforms, activating receptor CD32a and inhibitory receptor CD32b. Ligation of 
CD32a leads to DC maturation, increased stimulation of allogeneic T cells, and 
enhanced secretion of inflammatory cytokines, with the exception of IL-12p70. 
Co-ligation of CD32b limits activation via CD32a and hence reduces the 
immunogenicity of moDCs (Boruchov et al., 2005). In our study, the blocking 
antibody against CD32 can not tell these two isoforms apart. Therefore, specific 
antibodies against either CD32a or CD32b are required to study their roles 
individually. However, according to the function of these two isoforms documented, 
most likely induction of IL-1β secretion is mediated by the activating CD32a rather 
than the inhibitory CD32b.  
 
4.3 FcγR crosslinking triggers P2X7R-mediated Ca2+ influx 
 113
The P2X7R-mediated IL-1β secretion model has been well established (Dinarello, 
2005). As described in this model, activation of P2X7R triggers the efflux of 
potassium ions out of the cell, which in turn mediates the influx of calcium. Within 
minutes, the secretory lysosomes begin releasing their contents of processed IL-1β 
into the extracellular milieu. Therefore, in our study, a series of experiments were 
performed to assess whether imIgG-promoted IL-1β secretion was associated with the 
above model. First, we confirmed that moDCs indeed expressed functional p2X7R 
(Georgiou et al., 2005). Our results showed that (i) moDC expressed P2X7R mRNA; 
(ii) ATP stimulation triggered rapid release of IL-1β from LPS-primed moDCs; and 
(iii) oATP, antagonist of P2X7R, inhibited ATP-induced IL-1β secretion. Second, we 
revealed the involvement of P2X7R in FcγR-mediated IL-1β release. Our data 
demonstrated that: (i) FcγR ligation up-regulated P2X7R gene expression; (ii) oATP 
suppressed IL-1β secretion by moDCs costimulated with LPS and imIgG; (iii) the 
conditioned culture medium from imIgG-primed moDC enhanced IL-1β secretion 
from LPS-stimulated moDCs; and (iv) blockade of calcium influx by extracellular 
calcium chelator EGTA significantly reduced IL-1β secretion from LPS/ 
imIgG-co-stimulated moDCs. To further confirm the role of P2X7R in FcγR-mediated 
IL-1β release, a specific monoclonal blocking antibody against P2X7R has to be 
generated. Pre-treatment of moDCs with this antibody would be expected to inhibit 
IL-1β secretion from LPS/ imIgG-co-stimulated moDCs.  
 
 114
ATP is the ligand for P2X7R. It is stored in the cytosol of most cells at a concentration 
of 5–10 mM and can be found in the 100 mM range in intracellular compartments. 
Due to its size and high density of charge, ATP cannot permeate membranes. 
However, release of ATP has been observed from a variety of cells, including tumor 
cells and lymphocytes, as well as from virtually all tissues under conditions of 
hypoxia, ischemia, inflammation, and cell necrosis (Baricordi et al., 1999; Bodin and 
Burnstock, 1995; Bodin and Burnstock, 1998; Pedersen et al., 1999). It has been 
reported in microglial cells and monocyte-derived human macrophages that LPS 
activated an autocrine/ paracrine loop of ATP that drives ATP-dependent 
P2X7R-mediated IL-1β secretion (Ferrari et al., 1997). In our study, there are two 
possible explanations for the enhanced IL-1β secretion from LPS-activated moDCs 
upon imIgG co-stimulation: (i) FcγR crosslinking increases the amount of ATP 
released from moDCs to overcome the P2X7R activation threshold. (ii) FcγR 
crosslinking up-regulates P2X7R expression on moDCs, which lowers the activation 
threshold of P2X7R. This implies that FcγR can modulate ATP-mediated immune 
responses.  
 
4.4 Investigation of signaling molecules involved in the regulation of IL-1β 
production 
Little has been characterized about the essential intracellular signal transduction 
molecules between initial stimulation and ultimate IL-1β release. In our study, TLR 
and FcγR pathways appear to crosstalk with each other in IL-1β regulation. Using 
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specific pharmacological inhibitors, we identified a few critical modulators: (i) PI3-K 
and p38 MAPK down-regulated IL-1β secretion; (ii) JNK and ERK MAPKs 
up-regulated IL-1β release; and (iii) Rac1 was crucial for optimal IL-1β secretion 
from LPS/ imIgG-co-stimulated moDCs. 
 
In cells of the mammalian immune system, signaling via PI3K regulates cell 
proliferation, survival, differentiation, chemotaxis, phagocytosis, degranulation, and 
respiratory burst (Fruman and Cantley, 2002). Previous studies have reported the 
negative regulatory role of PI3-K-Akt pathway in inflammatory response. In human 
monocytes and THP-1 cells, inhibition of PI3K enhanced LPS-induced nuclear 
translocation of NF-κB, activation of the MAPK pathways and the downstream 
targets AP-1 and Egr-1. It also led to excessive expression of TNF-α and tissure 
factor (TF) (Guha and Mackman, 2002). In addition, PI3-K inhibitor−treated DCs 
produced increased amount of IL-12. Upon Leishmania major infection, PI3K-/- mice 
displayed enhanced T helper type 1 (TH1) response (Fukao et al., 2002). In this study, 
our data provide addition evidence to support the existence of negative feedback 
mechanism via PI3-K. LY294002, the specific PI3-K inhibitor, led to enhanced 
IL-1β secretion from LPS-activated moDCs. PI3-K inhibition may up-regulate 
IL-1β mRNA expression through increased NF-κB nuclear translocation and 
enhanced activity of MAPKs and their down stream transcriptional factor. In order to 
examine this, a series of experiments can be performed in the future study. moDCs 
will be stimulated with LPS in the presence or absence of LY294002. (i) IL-1β gene 
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expression in these cells can be quantified by real-time. (ii) The phosphorylation of 
ERK, p38 and JNK MAPKs can be analyzed by western blotting. (iii) The nuclear 
translocation of NF-κB can be evaluated by nuclear extract western blotting or 
electrophoretic mobility supershift assays (EMSA). In addition, it is also possible that 
PI3-K suppresses key elements in IL-1β secretion apparatus.  
 
The MAPKs are one of the most ancient and evolutionarily conserved signaling 
pathways (Dong et al., 2002). They are important for many processes in immune 
responses. Three major groups of MAPKs have been identified in mammalian cells: 
ERK, p38 and JNK. ERK inhibition prevents the transport of TNF-α mRNA from the 
nucleus to the cytoplasm (Dumitru et al., 2000). It is possible that this 
posttranscriptional regulation applies to IL-1β as well. JNK is required for MMPs 
expression and joint destruction in inflammatory arthritis. JNK inhibition retards or 
even prevents tissue damage in animal models of RA (Han et al., 2001). Therefore, if 
the processing of pro-IL-1β in LPS/ imIgG-co-stimulated moDCs is partially 
dependent on MMPs as we discussed in 4.2, inhibition of JNK may suppress MMPs 
expression and lead to reduced IL-1β processing and subsequent secretion. P38 
inhibition suppresses LPS-mediated TNF-α production by macrophages (Lee et al., 
1994). It also prevents the transcriptional activation of both IL-1α and IL-1β genes in 
LPS-stimulated mouse bone-marrow derived macrophages and  J774A.1 
macrophage-like cells (Park et al., 2002). And p38 inhibitors have been shown to 
inhibit the development of CIA in rats (Nishikawa et al., 2003). However, our data 
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showed that p38 inhibition enhanced IL-1β release from LPS-stimulated moDCs. The 
enhancement is even more obvious in LPS/ imIgG-co-stimulate moDCs. These results 
seem to contradict with previous reports. The cause of this discrepancy is unclear.  
 
The genetic deletion of Rac1 and Rac2 has been reported to prevent phagocytosis 
mediated by FcγR (Hall et al., 2006). In this project, we demonstrated that Rac1 
inhibition abrogated FcγR-promoted IL-1β secretion. This finding suggests that 
FcγR-mediated IL-1β secretion is not a passive non-selective leakage of intracellular 
protein due to apoptosis or cell death, but a well-organized selective exocytosis 
controlled by the activity of Rac1. This supports the model of PLA2-mediated 
exocytosis of lysosomal vesicles for IL-1β secretion (Andrei et al., 1999). 
 
4.5 FcγRs, IL-1 and autoimmune disease 
Despite their essential role in host protection, immunoglobulins are also involved in 
autoimmune processes where antibodies recognized the host’s own tissue antigens, 
triggering inflammatory responses that result in extensive tissue damage. The 
contribution of gene deficiencies and polymorphisms of FcγRs to the pathology of 
human autoimmune disease has been reviewed by Fossati (Fossati et al., 2001). And 
this is further supported by in vivo studies of autoimmunity in mice lacking FcγR. 
FcR γ-/- mice generated, deposited immune complex and activated complement, but 
they were protected from severe nephritis (Clynes et al., 1998). Similar protection 
from tissue damage upon FcR γ-chain knock out was also observed in model of 
 118
anti-glomerular basement membrane glomerulonephritis (Park et al., 1998) and CIA 
(Kleinau et al., 2000). Conversely, the inhibitory FcγRIIb was shown to suppress 
FcγR-mediated activation in these models (Kleinau et al., 2000; Yuasa et al., 1999). 
FcγRIIa is only found in humans and higher primates but not mice. Therefore, its role 
has been investigated recently with hFcγRIIa transgenic mice (Hogarth, 2002). These 
mice were profoundly sensitive to antibody-induced inflammation and developed a 
spontaneous autoimmune syndrome with features similar to RA. Moreover, the 
presence of the hFcγRIIa made genetically resistant mice susceptible to CIA. Hence, 
FcγRs, especially FcγRIIa, play an essential role in autoimmune disease development. 
 
Analysis of cytokine and protein in RA tissue revealed that many pro-inflammatory 
cytokines such as TNF-a, IL-1, IL-6, GM-CSF, and chemokines such as IL-8 are 
abundant in all patients regardless of therapy (Feldmann et al., 1996).  Among them, 
IL-1 has attracted great interest. IL-1α/β-/- mice have suppressed development of 
arthritis in both CIA model (Saijo et al., 2002) and HTLV-1 Tg (human T-cell 
leukemia virus type I transgenic mouse) model (Iwakura, 2002).  Treatment with 
anti-IL-1α/β or anti-IL-1β antibodies, ameliorated CIA in mice (Joosten et al., 1996; 
van den Berg et al., 1994). IL-1 has been implicated to be involved in all phases of 
RA development. At the initiation and perpetuation phase, IL-1β is secreted by DCs, 
which presented arthritogenic antigen to auto-reactive T cells (Summers et al., 1995; 
Thomas and Lipsky, 1996; Thomas and Quinn, 1996). The secreted IL-1β acts on 
IL-1R expressed on the T cells. The activation of IL-1R up-regulates CD40L and 
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OX-40 expression on T cells (Luft et al., 2002), which enhances T cell-dependent 
antibody production (Nakae et al., 2001). In CIA model, anti-CD40L blocked the 
development of joint inflammation, serum antibody titers to collagen, the infiltration 
of inflammatory cells into the subsynovial tissue, and the erosion of cartilage and 
bone (Durie et al., 1993). Moreover, IL-1β has also been found to play a role at the 
effector phase of RA. IL-1β promotes synovial cell growth and activates synovial 
cells and osteroclasts to produce MMPs and collagenases that cause erosion of the 
bone and cartilage of joints (Iwakura, 2002). Therefore, IL-1β is an important 
pathogenic element in autoimmune disease condition. 
 
Our study indicates that FcγR crosslinking attenuates the stringent control over 
IL-1β regulation in moDC. It induces secretion of IL-1β from DCs that are 
co-stimulated with microbial structures. This finding provides the first piece of 
evidence to link FcγR with IL-1β, both of which are important pathogenic elements in 
autoimmune disease as we mentioned above. Based on our results, a hypothesis has 
been proposed to explain the linkage between FcγR and IL-1β in the development of 
RA. In RA, DCs are chronically exposed to ICs deposited on the synovium. The 
activation of FcγR may loosen the stringent control over IL-1β production and leads 
to excessive IL-1β secretion. The overproduction of IL-1 in turn accelerates the 
disease progression. This hypothesis can be verified by using FcR γ-/- mice in CIA 
model. These mice model have to be generated for future study. FcR γ-/- mice and 
their wild type counterparts will be intradermally injected with type II collagen. 
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Synovial fluid from these mice will be collected for cytokine analysis by ELISA, in 
particular IL-1β. The level of IL-1β in the synovial fluid of FcR γ-/- mice would be 
expected to be lower than that of wild type mice.  
 
In summary, this project has revealed new mechanisms for the regulation of IL-1β 
production in moDCs, and its implication in inflammation and autoimmunity.  
 
 121
APPENDIX: Media and Solutions 
LB-agar plates 
15 g/L Bacto-agar was added to LB-broth. Media was sterilized by autoclaving. 
50×TAE buffer for DNA gel electrophoresis 
Tris base  2 M 
Acetic acid  1 M 
EDTA 0.1 M 
5×DNA sample loading buffer 
Ficoll 400 15% (v/v) 
Na2EDTA (pH 8.0) 0.1 M 
Bromophenol blue 0.025% (w/v) 
Xylene cyanol 0.25% (w/v) 
1× PBS 
KH2PO4 1.76 mM 
Na2HPO4 10.4 mM 
NaCl 137 mM 
KCl 2.7 mM 
FACS buffer 
BCS 2% (v/v) 
Sodium azide 0.05% (w/v) 
in PBS  
Hypertonic lysis buffer in caspase-1 activity assay 
HEPES pH 7.5 25 mM 
MgCl2 5 mM 
EDTA 5 mM 
DTT 5 mM 
PMSF 2 mM 
Aprotonin (Sigma) 10 µg/ml 
Lysis buffer in SDS-PAGE 
Tris pH 7.5 20 mM 
NaCl 300 mM 
KCl 20 mM 
EDTA 2 mM 
EGTA 2 mM 
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Trition X-100 1% (v/v) 
Leupeptin (Sigma) 10 µg/ml 
Aprotinin (Sigma) 10 µg/ml 
PMSF 2 mM 
SDS-PAGE stacking gel 
dH2O 3.05 ml 
0.5M Tris-HCl, pH 6.8 1.25 ml 
10% (w/v) SDS 50 µl 
30% Acrylamide/Bis Solution 29:1 (3.3% C) 0.65 ml 
10% APS 25 µl 
TEMED 5 µl 
12.5% SDS-PAGE separating gel  
dH2O 3.17 ml 
1.5M Tris-HCl, pH 8.8 2.5 ml 
10% (w/v) SDS 100 µl 
30% Acrylamide/Bis Solution 29:1 (3.3% C) 4.16 ml 
10% APS 50 µl 
TEMED 5 µl 
5× SDS-PAGE reducing sample loading buffer 
Tris-Cl pH 6.8 60 mM 
Glycerol 24% (v/v) 
SDS 2% 
β-mercaptoethanol 14.4 mM 
Bromophenol blue 1% (w/v) 
10× Western blot transfer buffer 
Tris base 25 mM 
Glycine 192 mM 
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